US20110263686A1 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof - Google Patents

Antisense oligonucleotides for inducing exon skipping and methods of use thereof Download PDF

Info

Publication number
US20110263686A1
US20110263686A1 US13168857 US201113168857A US2011263686A1 US 20110263686 A1 US20110263686 A1 US 20110263686A1 US 13168857 US13168857 US 13168857 US 201113168857 A US201113168857 A US 201113168857A US 2011263686 A1 US2011263686 A1 US 2011263686A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
exon
skipping
antisense
antisense oligonucleotide
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13168857
Inventor
Stephen Donald Wilton
Sue Fletcher
Graham McClorey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3519Fusion with another nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/33Alteration of splicing

Abstract

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Description

    FIELD OF THE INVENTION
  • The present invention relates to novel antisense compounds and compositions suitable for facilitating exon skipping. It also provides methods for inducing exon skipping using the novel antisense compounds as well as therapeutic compositions adapted for use in the methods of the invention.
  • BACKGROUND ART
  • Significant effort is currently being expended researching methods for suppressing or compensating for disease-causing mutations in genes. Antisense technologies are being developed using a range of chemistries to affect gene expression at a variety of different levels (transcription, splicing, stability, translation). Much of that research has focused on the use of antisense compounds to correct or compensate for abnormal or disease-associated genes in a myriad of different conditions.
  • Antisense molecules are able to inhibit gene expression with exquisite specificity and because of this many research efforts concerning oligonucleotides as modulators of gene expression have focused on inhibiting the expression of targeted genes such as oncogenes or viral genes. The antisense oligonucleotides are directed either against RNA (sense strand) or against DNA where they form triplex structures inhibiting transcription by RNA polymerase II. To achieve a desired effect in specific gene down-regulation, the oligonucleotides must either promote the decay of the targeted mRNA or block translation of that mRNA, thereby effectively preventing de novo synthesis of the undesirable target protein.
  • Such techniques are not useful where the object is to up-regulate production of the native protein or compensate for mutations which induce premature termination of translation such as nonsense or frame-shifting mutations. Furthermore, in cases where a normally functional protein is prematurely terminated because of mutations therein, a means for restoring some functional protein production through antisense technology has been shown to be possible through intervention during the splicing processes (Sierakowska H, et al., (1996) Proc Natl Acad Sci USA 93, 12840-12844; Wilton S D, et al., (1999) Neuromusc Disorders 9, 330-338; van Deutekom J C et al., (2001) Human Mol Genet 10, 1547-1554). In these cases, the defective gene transcript should not be subjected to targeted degradation so the antisense oligonucleotide chemistry should not promote target mRNA decay.
  • In a variety of genetic diseases, the effects of mutations on the eventual expression of a gene can be modulated through a process of targeted exon skipping during the splicing process. The splicing process is directed by complex multi-particle machinery that brings adjacent exon-intron junctions in pre-mRNA into close proximity and performs cleavage of phosphodiester bonds at the ends of the introns with their subsequent reformation between exons that are to be spliced together. This complex and highly precise process is mediated by sequence motifs in the pre-mRNA that are relatively short semi-conserved RNA segments to which bind the various nuclear splicing factors that are then involved in the splicing reactions. By changing the way the splicing machinery reads or recognises the motifs involved in pre-mRNA processing, it is possible to create differentially spliced mRNA molecules. It has now been recognised that the majority of human genes are alternatively spliced during normal gene expression, although the mechanisms invoked have not been identified. Using antisense oligonucleotides, it has been shown that errors and deficiencies in a coded mRNA could be bypassed or removed from the mature gene transcripts.
  • In nature, the extent of genetic deletion or exon skipping in the splicing process is not fully understood, although many instances have been documented to occur, generally at very low levels (Sherrat T G, et al., (1993) Am J Hum Genet 53, 1007-1015). However, it is recognised that if exons associated with disease-causing mutations can be specifically deleted from some genes, a shortened protein product can sometimes be produced that has similar biological properties of the native protein or has sufficient biological activity to ameliorate the disease caused by mutations associated with the target exon (Lu Q L, et al., (2003) Nature Medicine 9, 1009-1014; Aartsma-Rus A et al., (2004) Am J Hum Genet 74: 83-92).
  • This process of targeted exon skipping is likely to be particularly useful in long genes where there are many exons and introns, where there is redundancy in the genetic constitution of the exons or where a protein is able to function without one or more particular exons (e.g. with the dystrophin gene, which consists of 79 exons; or possibly some collagen genes which encode for repeated blocks of sequence or the huge nebulin or titin genes which are comprised of ˜80 and over 370 exons, respectively).
  • Efforts to redirect gene processing for the treatment of genetic diseases associated with truncations caused by mutations in various genes have focused on the use of antisense oligonucleotides that either: (1) fully or partially overlap with the elements involved in the splicing process; or (2) bind to the pre-mRNA at a position sufficiently close to the element to disrupt the binding and function of the splicing factors that would normally mediate a particular splicing reaction which occurs at that element (e.g., binds to the pre-mRNA at a position within 3, 6, or 9 nucleotides of the element to be blocked).
  • For example, modulation of mutant dystrophin pre-mRNA splicing with antisense oligoribonucleotides has been reported both in vitro and in vivo. In one type of dystrophin mutation reported in Japan, a 52-base pair deletion mutation causes exon 19 to be removed with the flanking introns during the splicing process (Matsuo et al., (1991) J Clin Invest. 87:2127-2131). An in vitro minigene splicing system has been used to show that a 31-mer 2′-O-methyl oligoribonucleotide complementary to the 5′ half of the deleted sequence in dystrophin Kobe exon 19 inhibited splicing of wild-type pre-mRNA (Takeshima et al. (1995), J. Clin. Invest., 95, 515-520). The same oligonucleotide was used to induce exon skipping from the native dystrophin gene transcript in human cultured lymphoblastoid cells.
  • Dunckley et al., (1997) Nucleosides & Nucleotides, 16, 1665-1668 described in vitro constructs for analysis of splicing around exon 23 of mutated dystrophin in the mdx mouse mutant, a model for muscular dystrophy. Plans to analyse these constructs in vitro using 2′ modified oligonucleotides targeted to splice sites within and adjacent to mouse dystrophin exon 23 were discussed, though no target sites or sequences were given.
  • 2′-O-methyl oligoribonucleotides were subsequently reported to correct dystrophin deficiency in myoblasts from the mdx mouse from this group. An antisense oligonucleotide targeted to the 3′ splice site of murine dystrophin intron 22 was reported to cause skipping of the mutant exon as well as several flanking exons and created a novel in-frame dystrophin transcript with a novel internal deletion. This mutated dystrophin was expressed in 1-2% of antisense treated mdx myotubes. Use of other oligonucleotide modifications such as 2′-O-methoxyethyl phosphodiesters are described (Dunckley et al. (1998) Human Mol. Genetics, 5, 1083-90).
  • Thus, antisense molecules may provide a tool in the treatment of genetic disorders such as Duchenne Muscular Dystrophy (DMD). However, attempts to induce exon skipping using antisense molecules have had mixed success. Studies on dystrophin exon 19, where successful skipping of that exon from the dystrophin pre-mRNA was achieved using a variety of antisense molecules directed at the flanking splice sites or motifs within the exon involved in exon definition as described by Errington et al. (2003) J Gen Med 5, 518-527”.
  • In contrast to the apparent ease of exon 19 skipping, the first report of exon 23 skipping in the mdx mouse by Dunckley et al., (1998) is now considered to be reporting only a naturally occurring revertant transcript or artefact rather than any true antisense activity. In addition to not consistently generating transcripts missing exon 23, Dunckley et al., (1998) did not show any time course of induced exon skipping, or even titration of antisense oligonucleotides, to demonstrate dose dependent effects where the levels of exon skipping corresponded with increasing or decreasing amounts of antisense oligonucleotide. Furthermore, this work could not be replicated by other researchers.
  • The first example of specific and reproducible exon skipping in the mdx mouse model was reported by Wilton et al., (1999) Neuromuscular Disorders 9, 330-338. By directing an antisense molecule to the donor splice site, consistent and efficient exon 23 skipping was induced in the dystrophin mRNA within 6 hours of treatment of the cultured cells. Wilton et al., (1999), also describe targeting the acceptor region of the mouse dystrophin pre-mRNA with longer antisense oligonucleotides and being unable to repeat the published results of Dunckley et al., (1998). No exon skipping, either 23 alone or multiple removal of several flanking exons, could be reproducibly detected using a selection of antisense oligonucleotides directed at the acceptor splice site of intron 22.
  • While the first antisense oligonucleotide directed at the intron 23 donor splice site induced consistent exon skipping in primary cultured myoblasts, this compound was found to be much less efficient in immortalized cell cultures expressing higher levels of dystrophin. However, with refined targeting and antisense oligonucleotide design, the efficiency of specific exon removal was increased by almost an order of magnitude (see Mann C J et al., (2002) J Gen Med 4, 644-654).
  • Thus, there remains a need to provide antisense oligonucleotides capable of binding to and modifying the splicing of a target nucleotide sequence. Simply directing the antisense oligonucleotides to motifs presumed to be crucial for splicing is no guarantee of the efficacy of that compound in a therapeutic setting.
  • SUMMARY OF THE INVENTION
  • The present invention provides antisense molecule compounds and compositions suitable for binding to RNA motifs involved in the splicing of pre-mRNA that are able to induce specific and efficient exon skipping and a method for their use thereof.
  • The choice of target selection plays a crucial role in the efficiency of exon skipping and hence its subsequent application of a potential therapy. Simply designing antisense molecules to target regions of pre-mRNA presumed to be involved in splicing is no guarantee of inducing efficient and specific exon skipping. The most obvious or readily defined targets for splicing intervention are the donor and acceptor splice sites although there are less defined or conserved motifs including exonic splicing enhancers, silencing elements and branch points.
  • The acceptor and donor splice sites have consensus sequences of about 16 and 8 bases respectively (see FIG. 1 for schematic representation of motifs and domains involved in exon recognition, intron removal and the splicing process).
  • According to a first aspect, the invention provides antisense molecules capable of binding to a selected target to induce exon skipping.
  • For example, to induce exon skipping in exons 3 to 8, 10 to 16, 19 to 40, 42 to 44, 46, 47, and 50 to 53 in the Dystrophin gene transcript the antisense molecules are preferably selected from the group listed in Table 1A.
  • In a further example, it is possible to combine two or more antisense oligonucleotides of the present invention together to induce multiple exon skipping in exons 19-20, and 53. This is a similar concept to targeting of a single exon. A combination or “cocktail” of antisense oligonucleotides are directed at adjacent exons to induce efficient exon skipping.
  • In another example, to induce exon skipping in exons 19-20, 31, 34 and 53 it is possible to improve exon skipping of a single exon by joining together two or more antisense oligonucleotide molecules. This concept is termed by the inventor as a “weasel”, an example of a cunningly designed antisense oligonucleotide. A similar concept has been described in Aartsma-Rus A et al., (2004) Am J Hum Genet 74: 83-92).
  • According to a second aspect, the present invention provides antisense molecules selected and or adapted to aid in the prophylactic or therapeutic treatment of a genetic disorder comprising at least an antisense molecule in a form suitable for delivery to a patient.
  • According to a third aspect, the invention provides a method for treating a patient suffering from a genetic disease wherein there is a mutation in a gene encoding a particular protein and the affect of the mutation can be abrogated by exon skipping, comprising the steps of: (a) selecting an antisense molecule in accordance with the methods described herein; and (b) administering the molecule to a patient in need of such treatment.
  • The invention also addresses the use of purified and isolated antisense oligonucleotides of the invention, for the manufacture of a medicament for treatment of a genetic disease.
  • The invention further provides a method of treating a condition characterised by Duchenne muscular dystrophy, which method comprises administering to a patient in need of treatment an effective amount of an appropriately designed antisense oligonucleotide of the invention, relevant to the particular genetic lesion in that patient. Further, the invention provides a method for prophylactically treating a patient to prevent or at least minimise Duchenne muscular dystrophy, comprising the step of: administering to the patient an effective amount of an antisense oligonucleotide or a pharmaceutical composition comprising one or more of these biological molecules.
  • The invention also provides kits for treating a genetic disease, which kits comprise at least a antisense oligonucleotide of the present invention, packaged in a suitable container and instructions for its use.
  • Other aspects and advantages of the invention will become apparent to those skilled in the art from a review of the ensuing description, which proceeds with reference to the following figures.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 Schematic representation of motifs and domains involved in exon recognition, intron removal and the splicing process.
  • FIG. 2. Diagrammatic representation of the concept of antisense oligonucleotide induced exon skipping to by-pass disease-causing mutations (not drawn to scale). The hatched box represents an exon carrying a mutation that prevents the translation of the rest of the mRNA into a protein. The solid black bar represents an antisense oligonucleotide that prevents inclusion of that exon in the mature mRNA.
  • FIG. 3 Gel electrophoresis showing differing efficiencies of two antisense molecules directed at exon 8 acceptor splice site. The preferred compound [H8A(−06+18)] induces strong and consistent exon skipping at a transfection concentration of 20 nanomolar in cultured normal human muscle cells. The less preferred antisense oligonucleotide [H8A(−06+14)] also induces efficient exon skipping, but at much higher concentrations. Other antisense oligonucleotides directed at exon 8 either only induced lower levels of exon skipping or no detectable skipping at all (not shown).
  • FIG. 4 Gel electrophoresis showing differing efficiencies of two antisense molecules directed at internal domains within exon 7, presumably exon splicing enhancers. The preferred compound [H7A(+45+67)] induces strong and consistent exon skipping at a transfection concentration of 20 nanomolar in cultured human muscle cells. The less preferred antisense oligonucleotide [H7A(+2+26)] induces only low levels of exon skipping at the higher transfection concentrations. Other antisense oligonucleotides directed at exon 7 either only induced lower levels of exon skipping or no detectable skipping at all (not shown).
  • FIG. 5 Gel electrophoresis showing an example of low efficiency exon 6 skipping using two non-preferred antisense molecules directed at human exon 6 donor splice site. Levels of induced exon 6 skipping are either very low [H6D(+04−21)] or almost undetectable [H6D(+18−04)]. These are examples of non-preferred antisense oligonucleotides to demonstrate that antisense oligonucleotide design plays a crucial role in the efficacy of these compounds.
  • FIG. 6 Gel electrophoresis showing strong and efficient human exon 6 skipping using an antisense molecules [H6A(+69+91)] directed at an exon 6 internal domain, presumably an exon splicing enhancer. This preferred compound induces consistent exon skipping at a transfection concentration of 20 nanomolar in cultured human muscle cells.
  • FIG. 7 Gel electrophoresis showing strong human exon 4 skipping using an antisense molecule H4A(+13+32) directed at an exon 6 internal domain, presumably an exon splicing enhancer. This preferred compound induces strong and consistent exon skipping at a transfection concentration of 20 nanomolar in cultured human muscle cells.
  • FIG. 8 Gel electrophoresis showing (8B) strong human exon 11 skipping using antisense molecule H11A(+75+97) directed at an exon 11 internal domain; and (8B) strong human exon 12 skipping using antisense molecule H12A(+52+75) directed at exon 12 internal domain.
  • FIG. 9 Gel electrophoresis showing (9A) strong human exon 15 skipping using antisense molecules H15A(+48+71) and H15A(−12+19) directed at an exon 15 internal domain; and (9B) strong human exon 16 skipping using antisense molecules H16A(−12+19) and H16A(−06+25).
  • FIG. 10 Gel electrophoresis showing human exon 19/20 skipping using antisense molecules H20A(+44+71) and H20A(+149+170) directed at an exon 20 and a “cocktail” of antisense oligonucleotides H19A(+35+65, H20A(+44+71) and H20A(+149+170) directed at exons 19/20.
  • FIG. 11 Gel electrophoresis showing human exon 19/20 skipping using “weasels” directed at exons 19 and 20.
  • FIG. 12 Gel electrophoresis showing exon 22 skipping using antisense molecules H22A(+125+106), H22A(+47+69), H22A(+80+101) and H22D(+13−11) directed at exon 22.
  • FIG. 13 Gel electrophoresis showing exon 31 skipping using antisense molecules H31D(+01−25) and H31D(+03−22); and a “cocktail” of antisense molecules directed at exon 31.
  • FIG. 14 Gel electrophoresis showing exon 33 skipping using antisense molecules H33A(+30+56) and H33A(+64+88) directed at exon 33.
  • FIG. 15 Gel electrophoresis showing exon 35 skipping using antisense molecules H35A(+141+161), H35A(+116+135), and H35A(+24+43) and a “cocktail of two antisense molecules, directed at exon 35.
  • FIG. 16 Gel electrophoresis showing exon 36 skipping using antisense molecules H32A(+49+73) and H36A(+26+50) directed at exon 36.
  • FIG. 17 Gel electrophoresis showing exon 37 skipping using antisense molecules H37A(+82+105) and H37A(+134+157) directed at exon 37.
  • FIG. 18 Gel electrophoresis showing exon 38 skipping using antisense molecule H38A(+88+112) directed at exon 38.
  • FIG. 19 Gel electrophoresis showing exon 40 skipping using antisense molecule H40A(−05+17) directed at exon 40.
  • FIG. 20 Gel electrophoresis showing exon 42 skipping using antisense molecule H42A(−04+23) directed at exon 42.
  • FIG. 21 Gel electrophoresis showing exon 46 skipping using antisense molecule H46A(+86+115) directed at exon 46
  • FIG. 22 Gel electrophoresis showing exon 51, exon 52 and exon 53 skipping using various antisense molecules directed at exons 51, 52 and 53, respectively. A “cocktail” of antisense molecules is also shown directed at exon 53.
  • TABLE 1A
    Description of 2′-O-methyl phosphorothioate antisense
    oligonucleotides that have been used to date to study
    induced exon skipping during the processing of the
    dystrophin pre-mRNA. Since these 2′-O-methyl antisense
    oligonucleotides are more RNA-like, U represents
    uracil. With other antisense chemistries such as pep-
    tide nucleic acids or morpholinos, these U bases may
    be shown as “T”.
    Brief Description of the Sequence listings
    SEQ ID SEQUENCE NUCLEOTIDE SEQUENCE (5′-3′)
      1 H8A(−06 +18) GAU AGG UGG UAU CAA CAU CUG UAA
      2 H8A(−03 +18) GAU AGG UGG UAU CAA CAU CUG
      3 H8A(−07 +18) GAU AGG UGG UAU CAA CAU CUG UAA G
      4 H8A(−06 +14) GGU GGU AUC AAC AUC UGU AA
      5 H8A(−10 +10) GUA UCA ACA UCU GUA AGC AC
      6 H7A(+45 +67) UGC AUG UUC CAG UCG UUG UGU GG
      7 H7A(+02 +26) CAC UAU UCC AGU CAA AUA GGU CUG G
      8 H7D(+15 −10) AUU UAC CAA CCU UCA GGA UCG AGU A
      9 H7A(−18 +03) GGC CUA AAA CAC AUA CAC AUA
     10 C6A(−10 +10) CAU UUU UGA CCU ACA UGU GG
     11 C6A(−14 +06) UUU GAC CUA CAU GUG GAA AG
     12 C6A(−14 +12) UAC AUU UUU GAC CUA CAU GUG GAA AG
     13 C6A(−13 +09) AUU UUU GAC CUA CAU GGG AAA G
     14 CH6A(+69 +91) UAC GAG UUG AUU GUC GGA CCC AG
     15 C6D(+12 −13) GUG GUC UCC UUA CCU AUG ACU GUG G
     16 C6D(+06 −11) GGU CUC CUU ACC UAU GA
     17 H6D(+04 −21) UGU CUC AGU AAU CUU CUU ACC UAU
     18 H6D(+18 −04) UCU UAC CUA UGA CUA UGG AUG AGA
     19 H4A(+13 +32) GCA UGA ACU CUU GUG GAU CC
     20 H4D(+04 −16) CCA GGG UAC UAC UUA CAU UA
     21 H4D(−24 −44) AUC GUG UGU CAC AGC AUC CAG
     22 H4A(+11 +40) UGU UCA GGG CAU GAA CUC UUG UGG AUC
    CUU
     23 H3A(+30 +60) UAG GAG GCG CCU CCC AUC CUG UAG GUC
    ACU G
     24 H3A(+35 +65) AGG UCU AGG AGG CGC CUC CCA UCC UGU
    AGG U
     25 H3A(+30 +54) GCG CCU CCC AUC CUG UAG GUC ACU G
     26 H3D(+46 −21) CUU CGA GGA GGU CUA GGA GGC GCC UC
     27 H3A(+30 +50) CUC CCA UCC UGU AGG UCA CUG
     28 H3D(+19 −03) UAC CAG UUU UUG CCC UGU CAG G
     29 H3A(−06 +20) UCA AUA UGC UGC UUC CCA AAC UGA AA
     30 H3A(+37 +61) CUA GGA GGC GCC UCC CAU CCU GUA G
     31 H5A(+20 +50) UUA UGA UUU CCA UCU ACG AUG UCA GUA
    CUU C
     32 H5D(+25 −05) CUU ACC UGC CAG UGG AGG AUU AUA UUC
    CAA A
     33 H5D(+10 −15) CAU CAG GAU UCU UAC CUG CCA GUG G
     34 H5A(+10 +34) CGA UGU CAG UAC UUC CAA UAU UCA C
     35 H5D(−04 −21) ACC AUU CAU CAG GAU UCU
     36 H5D(+16 −02) ACC UGC CAG UGG AGG AUU
     37 H5A(−07 +20) CCA AUA UUC ACU AAA UCA ACC UGU UAA
     38 H5D(+18 −12) CAG GAU UCU UAC CUG CCA GUG GAG GAU
    UAU
     39 H5A(+05 +35) ACG AUG UCA GUA CUU CCA AUA UUC ACU AAA
    U
     40 H5A(+15 +45) AUU UCC AUC UAC GAU GUC AGU ACU UCC
    AAU A
     41 H10A(−05 +16) CAG GAG CUU CCA AAU GCU GCA
     42 H10A(−05 +24) CUU GUC UUC AGG AGC UUC CAA AUG CUG CA
     43 H10A(+98 +119)  UCC UCA GCA GAA AGA AGC CAC G
     44 H10A(+130 +149) UUA GAA AUC UCU CCU UGU GC
     45 H10A(−33 −14) UAA AUU GGG UGU UAC ACA AU
     46 H11D(+26 +49) CCC UGA GGC AUU CCC AUC UUG AAU
     47 H11D(+11 −09) AGG ACU UAC UUG CUU UGU UU
     48 H11A(+118 +140) CUU GAA UUU AGG AGA UUC AUC UG
     49 H11A(+75 +97) CAU CUU CUG AUA AUU UUC CUG UU
     50 H12A(+52 +75) UCU UCU GUU UUU GUU AGC CAG UCA
     51 H12A(−10 +10) UCU AUG UAA ACU GAA AAU UU
     52 H12A(+11 +30) UUC UGG AGA UCC AUU AAA AC
     53 H13A(+77 +100) CAG CAG UUG CGU GAU CUC CAC UAG
     54 H13A(+55 +75) UUC AUC AAC UAC CAC CAC CAU
     55 H13D(+06 −19) CUA AGC AAA AUA AUC UGA CCU UAA G
     56 H14A(+37 +64) CUU GUA AAA GAA CCC AGC GGU CUU CUG U
     57 H14A(+14 +35) CAU CUA CAG AUG UUU GCC CAU C
     58 H14A(+51 +73) GAA GGA UGU CUU GUA AAA GAA CC
     59 H14D(−02 +18) ACC UGU UCU UCA GUA AGA CG
     60 H14D(+14 −10) CAU GAC ACA CCU GUU CUU CAG UAA
     61 H14A(+61 +80) CAU UUG AGA AGG AUG UCU UG
     62 H14A(−12 +12) AUC UCC CAA UAC CUG GAG AAG AGA
     63 H15A(−12 +19) GCC AUG CAC UAA AAA GGC ACU GCA AGA
    CAU U
     64 H15A(+48 +71) UCU UUA AAG CCA GUU GUG UGA AUC
     65 H15A(+08 +28) UUU CUG AAA GCC AUG CAC UAA
     66 H15D(+17 −08) GUA CAU ACG GCC AGU UUU UGA AGA C
     67 H16A(−12 +19) CUA GAU CCG CUU UUA AAA CCU GUU AAA ACA
    A
     68 H16A(−06 +25) UCU UUU CUA GAU CCG CUU UUA AAA CCU
    GUU A
     69 H16A(−06 +19) CUA GAU CCG CUU UUA AAA CCU GUU A
     70 H16A(+87 +109) CCG UCU UCU GGG UCA CUG ACU UA
     71 H16A(−07 +19) CUA GAU CCG CUU UUA AAA CCU GUU AA
     72 H16A(−07 +13) CCG CUU UUA AAA CCU GUU AA
     73 H16A(+12 +37) UGG AUU GCU UUU UCU UUU CUA GAU CC
     74 H16A(+92 +116) CAU GCU UCC GUC UUC UGG GUC ACU G
     75 H16A(+45 +67) G AUC UUG UUU GAG UGA AUA CAG U
     76 H16A(+105 +126) GUU AUC CAG CCA UGC UUC CGU C
     77 H16D(+05 −20) UGA UAA UUG GUA UCA CUA ACC UGU G
     78 H16D(+12 −11) GUA UCA CUA ACC UGU GCU GUA C
     79 H19A(+35 +53) CAG CAG UAG UUG UCA UCU GC
     80 H19A(+35 +65) GCC UGA GCU GAU CUG CUG GCA UCU UGC
    AGU U
     81 H20A(+44 +71) CUG GCA GAA UUC GAU CCA CCG GCU GUU C
     82 H20A(+149 +170) CAG CAG UAG UUG UCA UCU GCU C
     83 H20A(+185 +203) UGA UGG GGU GGU GGG UUG G
     84 H20A(−08 +17) AUC UGC AUU AAC ACC CUC UAG AAA G
     85 H20A(+30 +53) CCG GCU GUU CAG UUG UUC UGA GGC
     86 H20A(−11 +17) AUC UGC AUU AAC ACC CUC UAG AAA GAA A
     87 H20D(+08 −20) GAA GGA GAA GAG AUU CUU ACC UUA CAA A
     88 H20A(+44 +63) AUU CGA UCC ACC GGC UGU UC
     89 H20A(+149 +168 CUG CUG GCA UCU UGC AGU U
     90 H21A(−06 +16) GCC GGU UGA CUU CAU CCU GUG C
     91 H21A(+85 +106) CUG CAU CCA GGA ACA UGG GUC C
     92 H21A(+85 +108) GUC UGC AUC CAG GAA CAU GGG UC
     93 H21A(+08 +31) GUU GAA GAU CUG AUA GCC GGU UGA
     94 H21D(+18 −07) UAC UUA CUG UCU GUA GCU CUU UCU
     95 H22A(+22 +45) CAC UCA UGG UCU CCU GAU AGC GCA
     96 H22A(+125 +106) CUG CAA UUC CCC GAG UCU CUG C
     97 H22A(+47 +69) ACU GCU GGA CCC AUG UCC UGA UG
     98 H22A(+80 +101) CUA AGU UGA GGU AUG GAG AGU
     99 H22D(+13 −11) UAU UCA CAG ACC UGC AAU UCC CC
    100 H23A(+34 +59) ACA GUG GUG CUG AGA UAG UAU AGG CC
    101 H23A(+18 +39) UAG GCC ACU UUG UUG CUC UUG C
    102 H23A(+72 +90) UUC AGA GGG CGC UUU CUU C
    103 H24A(+48 +70) GGG CAG GCC AUU CCU CCU UCA GA
    104 H24A(−02 +22) UCU UCA GGG UUU GUA UGU GAU UCU
    105 H25A(+9 +36) CTG GGC UGA AUU GUC UGA AUA UCA CUG
    106 H25A(+131 +156) CUG UUG GCA CAU GUG AUC CCA CUG AG
    107 H25D(+16 −08) GUC UAU ACC UGU UGG CAC AUG UGA
    108 H26A(+132 +156) UGC UUU CUG UAA UUC AUC UGG AGU U
    109 H26A(−07 +19) CCU CCU UUC UGG CAU AGA CCU UCC AC
    110 H26A(+68 +92) UGU GUC AUC CAU UCG UGC AUC UCU G
    111 H27A(+82 +106) UUA AGG CCU CUU GUG CUA CAG GUG G
    112 H27A(−4 +19) GGG CCU CUU CUU UAG CUC UCU GA
    113 H27D(+19 −03) GAC UUC CAA AGU CUU GCA UUU C
    114 H28A(−05 +19) GCC AAC AUG CCC AAA CUU CCU AAG
    115 H28A(+99 +124) CAG AGA UUU CCU CAG CUC CGC CAG GA
    116 H28D(+16 −05) CUU ACA UCU AGC ACC UCA GAG
    117 H29A(+57 +81) UCC GCC AUC UGU UAG GGU CUG UGC C
    118 H29A(+18 +42) AUU UGG GUU AUC CUC UGA AUG UCG C
    119 H29D(+17 −05) CAU ACC UCU UCA UGU AGU UCU C
    120 H30A(+122 +147) CAU UUG AGC UGC GUC CAC CUU GUC UG
    121 H30A(+25 +50) UCC UGG GCA GAC UGG AUG CUC UGU UC
    122 H30D(+19 −04) UUG CCU GGG CUU CCU GAG GCA UU
    123 H31D(+06 −18) UUC UGA AAU AAC AUA UAC CUG UGC
    124 H31D(+03 −22) UAG UUU CUG AAA UAA CAU AUA CCU G
    125 H31A(+05 +25) GAC UUG UCA AAU CAG AUU GGA
    126 H31D(+04 −20) GUU UCU GAA AUA ACA UAU ACC UGU
    127 H32D(+04 −16) CAC CAG AAA UAC AUA CCA CA
    128 H32A(+151 +170) CAA UGA UUU AGC UGU GAC UG
    129 H32A(+10 +32) CGA AAC UUC AUG GAG ACA UCU UG
    130 H32A(+49 +73) CUU GUA GAC GCU GCU CAA AAU UGG C
    131 H33D(+09 −11) CAU GCA CAC ACC UUU GCU CC
    132 H33A(+53 +76) UCU GUA CAA UCU GAC GUC CAG UCU
    133 H33A(+30 +56) GUC UUU AUC ACC AUU UCC ACU UCA GAC
    134 H33A(+64 +88) CCG UCU GCU UUU UCU GUA CAA UCU G
    135 H34A(+83 +104) UCC AUA UCU GUA GCU GCC AGC C
    136 H34A(+143 +165) CCA GGC AAC UUC AGA AUC CAA AU
    137 H34A(−20 +10) UUU CUG UUA CCU GAA AAG AAU UAU AAU GAA
    138 H34A(+46 +70) CAU UCA UUU CCU UUC GCA UCU UAC G
    139 H34A(+95 +120) UGA UCU CUU UGU CAA UUC CAU AUC UG
    140 H34D(+10 −20) UUC AGU GAU AUA GGU UUU ACC UUU CCC
    CAG
    141 H34A(+72 +96) CUG UAG CUG CCA GCC AUU CUG UCA AG
    142 H35A(+141 +161) UCU UCU GCU CGG GAG GUG ACA
    143 H35A(+116 +135) CCA GUU ACU AUU CAG AAG AC
    144 H35A(+24 +43) UCU UCA GGU GCA CCU UCU GU
    145 H36A(+26 +50) UGU GAU GUG GUC CAC AUU CUG GUC A
    146 H36A(−02 +18) CCA UGU GUU UCU GGU AUU CC
    147 H37A(+26 +50) CGU GUA GAG UCC ACC UUU GGG CGU A
    148 H37A(+82 +105) UAC UAA UUU CCU GCA GUG GUC ACC
    149 H37A(+134 +157) UUC UGU GUG AAA UGG CUG CAA AUC
    150 H38A(−01 +19) CCU UCA AAG GAA UGG AGG CC
    151 H38A(+59 +83) UGC UGA AUU UCA GCC UCC AGU GGU U
    152 H38A(+88 +112) UGA AGU CUU CCU CUU UCA GAU UCA C
    153 H39A(+62 +85) CUG GCU UUC UCU CAU CUG UGA UUC
    154 H39A(+39 +58) GUU GUA AGU UGU CUC CUC UU
    155 H39A(+102 +121) UUG UCU GUA ACA GCU GCU GU
    156 H39D(+10 −10) GCU CUA AUA CCU UGA GAG CA
    157 H40A(−05 +17) CUU UGA GAC CUC AAA UCC UGU U
    158 H40A(+129 +153) CUU UAU UUU CCU UUC AUC UCU GGG C
    159 H42A(−04 +23) AUC GUU UCU UCA CGG ACA GUG UGC UGG
    160 H42A(+86 +109) GGG CUU GUG AGA CAU GAG UGA UUU
    161 H42D(+19 −02) A CCU UCA GAG GAC UCC UCU UGC
    162 H43D(+10 −15) UAU GUG UUA CCU ACC CUU GUC GGU C
    163 H43A(+101 +120) GGA GAG AGC UUC CUG UAG CU
    164 H43A(+78 +100) UCA CCC UUU CCA CAG GCG UUG CA
    165 H44A(+85 +104) UUU GUG UCU UUC UGA GAA AC
    166 H44D(+10 −10) AAA GAC UUA CCU UAA GAU AC
    167 H44A(−06 +14) AUC UGU CAA AUC GCC UGC AG
    168 H46D(+16 −04) UUA CCU UGA CUU GCU CAA GC
    169 H46A(+90 +109) UCC AGG UUC AAG UGG GAU AC
    170 H47A(+76 +100) GCU CUU CUG GGC UUA UGG GAG CAC U
    171 H47D(+25 −02) ACC UUU AUC CAC UGG AGA UUU GUC UGC
    172 H47A(−9 +12) UUC CAC CAG UAA CUG AAA CAG
    173 H50A(+02 +30) CCA CUC AGA GCU CAG AUC UUC UAA CUU CC
    174 H50A(+07 +33) CUU CCA CUC AGA GCU CAG AUC UUC UAA
    175 H50D(+07 −18) GGG AUC CAG UAU ACU UAC AGG CUC C
    176 H51A(−01 +25) ACC AGA GUA ACA GUC UGA GUA GGA GC
    177 H51D(+16 −07) CUC AUA CCU UCU GCU UGA UGA UC
    178 H51A(+111 +134) UUC UGU CCA AGC CCG GUU GAA AUC
    179 H51A(+61 +90) ACA UCA AGG AAG AUG GCA UUU CUA GUU
    UGG
    180 H51A(+66 +90) ACA UCA AGG AAG AUG GCA UUU CUA G
    181 H51A(+66 +95) CUC CAA CAU CAA GGA AGA UGG CAU UUC
    UAG
    182 H51D(+08 −17) AUC AUU UUU UCU CAU ACC UUC UGC U
    183 H51A/D(+08 −17) & AUC AUU UUU UCU CAU ACC UUC UGC UAG
    (−15 +) GAG CUA AAA
    184 H51A(+175 +195) CAC CCA CCA UCA CCC UCU GUG
    185 H51A(+199 +220) AUC AUC UCG UUG AUA UCC UCA A
    186 H52A(−07 +14) UCC UGC AUU GUU GCC UGU AAG
    187 H52A(+12 +41) UCC AAC UGG GGA CGC CUC UGU UCC AAA
    UCC
    188 H52A(+17 +37) ACU GGG GAC GCC UCU GUU CCA
    189 H52A(+93 +112) CCG UAA UGA UUG UUC UAG CC
    190 H52D(+05 −15) UGU UAA AAA ACU UAC UUC GA
    191 H53A(+45 +69) CAU UCA ACU GUU GCC UCC GGU UCU G
    192 H53A(+39 +62) CUG UUG CCU CCG GUU CUG AAG GUG
    193 H53A(+39 +69) CAU UCA ACU GUU GCC UCC GGU UCU GAA
    GGU G
    194 H53D(+14 −07) UAC UAA CCU UGG UUU CUG UGA
    195 H53A(+23 +47) CUG AAG GUG UUC UUG UAC UUC AUC C
    196 H53A(+150 +176) UGU AUA GGG ACC CUC CUU CCA UGA CUC
    197 H53D(+20 −05) CUA ACC UUG GUU UCU GUG AUU UUC U
    198 H53D(+09 −18) GGU AUC UUU GAU ACU AAC CUU GGU UUC
    199 H53A(−12 +10) AUU CUU UCA ACU AGA AUA AAA G
    200 H53A(−07 +18) GAU UCU GAA UUC UUU CAA CUA GAA U
    201 H53A(+07 +26) AUC CCA CUG AUU CUG AAU UC
    202 H53A(+124 +145) UUG GCU CUG GCC UGU CCU AAG A
    203 H46A(+86 +115) CUC UUU UCC AGG UUC AAG UGG GAU ACU
    AGC
    204 H46A(+107 +137) CAA GCU UUU CUU UUA GUU GCU GCU CUU
    UUC C
    205 H46A(−10 +20) UAU UCU UUU GUU CUU CUA GCC UGG AGA
    AAG
    206 H46A(+50 +77) CUG CUU CCU CCA ACC AUA AAA CAA AUU
    C
    207 H45A(−06 +20) CCA AUG CCA UCC UGG AGU UCC UGU AA
    208 H45A(+91 +110) UCC UGU AGA AUA CUG GCA UC
    209 H45A(+125 +151) UGC AGA CCU CCU GCC ACC GCA GAU UCA
    210 H45D(+16 −04) CUA CCU CUU UUU UCU GUC UG
    211 H45A(+71 +90) UGU UUU UGA GGA UUG CUG AA
  • TABLE 1B
    Description of a cocktail of 2′-O-methyl phosphorothioate antisense
    oligonucleotides that have been used to date to study induced exon
    skipping during the processing of the dystrophin pre-mRNA.
    SEQ ID SEQUENCE NUCLEOTIDE SEQUENCE (5′-3′)
     81 H20A(+44 +71) CUG GCA GAA UUC GAU CCA CCG GCU GUU C
     82 H20A(+149 +170) CAG CAG UAG UUG UCA UCU GCU C
     79 H19A(+35 +65) GCC UGA GCU GAU CUG CUG GCA UCU UGC
     81 H20A(+44 +71) AGU U
     82 H20A(+149 +170) CUG GCA GAA UUC GAU CCA CCG GCU GUU C
    CAG CAG UAG UUG UCA UCU GCU C
    194 H53D(+14 −07) UAC UAA CCU UGG UUU CUG UGA
    195 H53A(+23 +47) CTG AAG GUG UUC UUG UAC UUC AUC C
    196 H53A(+150 +175) UGU AUA GGG ACC CUC CUU CCA UGA CUC
  • TABLE 1C
    Description of a “weasel” of 2′-O-methyl phosphorothioate
    antisense oligonucleotides that have been used to date to
    study induced exon skipping during the processing of the
    dystrophin pre-mRNA.
    SEQ ID SEQUENCE NUCELOTIDE SEQUENCE (5′-3′)
     80 H20A(+44 +71)- CUG GCA GAA UUC GAU CCA CCG GCU GUU C-
     82 H20A(+149 +170) CAG CAG UAG UUG UCA UCU GCU C
     81 H19A(+35 +53)- GCC UGA GCU GAU CUG CUG GCA UCU UGC
     88 H20A(+44 +63)- AGU U
     89 H20A(+149 +168) -AUU CGA UCU ACC GGC UGU UC-
    AA CUG CUG GCA UCU UGC AGU U
     80 H19A(+35 +53)- GCC UGA GCU GAU CUG CUG GCA UCU UGC
     88 H20A(+44 +63) AGU U
    -AUU CGA UCU ACC GGC UGU UC-
     80 H19A(+35 +53)- GCC UGA GCU GAU CUG CUG GCA UCU UGC
     89 H20A(+149 +168) AGU U
    -AA CUG CUG GCA UCU UGC AGU U
    138 H34A(+46 +70)- CAU UCA UUU CCU UUC GCA UCU UAC G-
    139 H34A(+94 +120) UGA UCU CUU UGU CAA UUC CAU AUC UG
    124 H31D(+03 −22)- UAG UUU CUG AAA UAA CAU AUA CCU G-
    UU- UU-
    144 H35A(+24 +43) UCU UCA GGU GCA CCU UCU GU
    195 H53A(+23 +47)- CUG AAG GUG UUC UUG UAC UUC AUC C-
    AA- UGU AUA GGG ACC CUC CUU CCA UGA CUC-
    196 H53A(+150 +175)- AA-
    AA- UAC UAA CCU UGG UUU CUG UGA
    194 H53D(+14 −07)
    Aimed at exons CAG CAG UAG UUG UCA UCU GCU CAA CUG
    19/20/20 GCA GAA UUC GAU CCA CCG GCU GUU CAA
    GCC UGA GCU GAU CUG CUC GCA UCU
    UGC AGU
  • DETAILED DESCRIPTION OF THE INVENTION General
  • Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variation and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
  • The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions and methods are clearly within the scope of the invention as described herein.
  • Sequence identity numbers (SEQ ID NO:) containing nucleotide and amino acid sequence information included in this specification are collected at the end of the description and have been prepared using the programme PatentIn Version 3.0. Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc.). The length, type of sequence and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (e.g. <400>1, <400>2, etc.).
  • An antisense molecules nomenclature system was proposed and published to distinguish between the different antisense molecules (see Mann et al., (2002) J Gen Med 4, 644-654). This nomenclature became especially relevant when testing several slightly different antisense molecules, all directed at the same target region, as shown below:

  • H#A/D(x:y).
  • The first letter designates the species (e.g. H: human, M: murine, C: canine) “#” designates target dystrophin exon number.
  • “A/D” indicates acceptor or donor splice site at the beginning and end of the exon, respectively.
  • (x y) represents the annealing coordinates where “−” or “+” indicate intronic or exonic sequences respectively. As an example, A(−6+18) would indicate the last 6 bases of the intron preceding the target exon and the first 18 bases of the target exon. The closest splice site would be the acceptor so these coordinates would be preceded with an “A”. Describing annealing coordinates at the donor splice site could be D(+2−18) where the last 2 exonic bases and the first 18 intronic bases correspond to the annealing site of the antisense molecule. Entirely exonic annealing coordinates that would be represented by A(+65+85), that is the site between the 65th and 85th nucleotide from the start of that exon.
  • The entire disclosures of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference. No admission is made that any of the references constitute prior art or are part of the common general knowledge of those working in the field to which this invention relates.
  • As used necessarily herein the term “derived” and “derived from” shall be taken to indicate that a specific integer may be obtained from a particular source albeit not directly from that source.
  • Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
  • Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.
  • DESCRIPTION OF THE PREFERRED EMBODIMENT
  • When antisense molecule(s) are targeted to nucleotide sequences involved in splicing in exons within pre-mRNA sequences, normal splicing of the exon may be inhibited causing the splicing machinery to by-pass the entire mutated exon from the mature mRNA. The concept of antisense oligonucleotide induced exon skipping is shown in FIG. 2. In many genes, deletion of an entire exon would lead to the production of a non-functional protein through the loss of important functional domains or the disruption of the reading frame. In some proteins, however, it is possible to shorten the protein by deleting one or more exons, without disrupting the reading frame, from within the protein without seriously altering the biological activity of the protein. Typically, such proteins have a structural role and or possess functional domains at their ends. The present invention describes antisense molecules capable of binding to specified dystrophin pre-mRNA targets and re-directing processing of that gene.
  • Antisense Molecules
  • According to a first aspect of the invention, there is provided antisense molecules capable of binding to a selected target to induce exon skipping. To induce exon skipping in exons of the Dystrophin gene transcript, the antisense molecules are preferably selected from the group of compounds shown in Table 1A. There is also provided a combination or “cocktail” of two or more antisense oligonucleotides capable of binding to a selected target to induce exon skipping. To induce exon skipping in exons of the Dystrophin gene transcript, the antisense molecules in a “cocktail” are preferably selected from the group of compounds shown in Table 1B. Alternatively, exon skipping may be induced by antisense oligonucleotides joined together “weasels” preferably selected from the group of compounds shown in Table 1C.
  • Designing antisense molecules to completely mask consensus splice sites may not necessarily generate any skipping of the targeted exon. Furthermore, the inventors have discovered that size or length of the antisense oligonucleotide itself is not always a primary factor when designing antisense molecules. With some targets such as exon 19, antisense oligonucleotides as short as 12 bases were able to induce exon skipping, albeit not as efficiently as longer (20-31 bases) oligonucleotides. In some other targets, such as murine dystrophin exon 23, antisense oligonucleotides only 17 residues long were able to induce more efficient skipping than another overlapping compound of 25 nucleotides.
  • The inventors have also discovered that there does not appear to be any standard motif that can be blocked or masked by antisense molecules to redirect splicing. In some exons, such as mouse dystrophin exon 23, the donor splice site was the most amenable to target to re-direct skipping of that exon. It should be noted that designing and testing a series of exon 23 specific antisense molecules to anneal to overlapping regions of the donor splice site showed considerable variation in the efficacy of induced exon skipping. As reported in Mann et al., (2002) there was a significant variation in the efficiency of bypassing the nonsense mutation depending upon antisense oligonucleotide annealing (“Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy”. J Gen Med 4: 644-654). Targeting the acceptor site of exon 23 or several internal domains was not found to induce any consistent exon 23 skipping.
  • In other exons targeted for removal, masking the donor splice site did not induce any exon skipping. However, by directing antisense molecules to the acceptor splice site (human exon 8 as discussed below), strong and sustained exon skipping was induced. It should be noted that removal of human exon 8 was tightly linked with the co-removal of exon 9. There is no strong sequence homology between the exon 8 antisense oligonucleotides and corresponding regions of exon 9 so it does not appear to be a matter of cross reaction. Rather the splicing of these two exons is inextricably linked. This is not an isolated instance as the same effect is observed in canine cells where targeting exon 8 for removal also resulted in the skipping of exon 9. Targeting exon 23 for removal in the mouse dystrophin pre-mRNA also results in the frequent removal of exon 22 as well. This effect occurs in a dose dependent manner and also indicates close coordinated processing of 2 adjacent exons.
  • In other targeted exons, antisense molecules directed at the donor or acceptor splice sites did not induce exon skipping while annealing antisense molecules to intra-exonic regions (i.e. exon splicing enhancers within human dystrophin exon 6) was most efficient at inducing exon skipping. Some exons, both mouse and human exon 19 for example, are readily skipped by targeting antisense molecules to a variety of motifs. That is, targeted exon skipping is induced after using antisense oligonucleotides to mask donor and acceptor splice sites or exon splicing enhancers.
  • To identify and select antisense oligonucleotides suitable for use in the modulation of exon skipping, a nucleic acid sequence whose function is to be modulated must first be identified. This may be, for example, a gene (or mRNA transcribed form the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. Within the context of the present invention, preferred target site(s) are those involved in mRNA splicing (i.e. splice donor sites, splice acceptor sites, or exonic splicing enhancer elements). Splicing branch points and exon recognition sequences or splice enhancers are also potential target sites for modulation of mRNA splicing.
  • Preferably, the present invention aims to provide antisense molecules capable of binding to a selected target in the dystrophin pre-mRNA to induce efficient and consistent exon skipping. Duchenne muscular dystrophy arises from mutations that preclude the synthesis of a functional dystrophin gene product. These Duchenne muscular dystrophy gene defects are typically nonsense mutations or genomic rearrangements such as deletions, duplications or micro-deletions or insertions that disrupt the reading frame. As the human dystrophin gene is a large and complex gene with the 79 exons being spliced together to generate a mature mRNA with an open reading frame of approximately 11,000 bases, there are many positions where these mutations can occur. Consequently, a comprehensive antisense oligonucleotide based therapy to address many of the different disease-causing mutations in the dystrophin gene will require that many exons can be targeted for removal during the splicing process.
  • Within the context of the present invention, preferred target site(s) are those involved in mRNA splicing (i.e. splice donor sites, splice acceptor sites or exonic splicing enhancer elements). Splicing branch points and exon recognition sequences or splice enhancers are also potential target sites for modulation of mRNA splicing.
  • The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, “specifically hybridisable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense molecule need not be 100% complementary to that of its target sequence to be specifically hybridisable. An antisense molecule is specifically hybridisable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.
  • While the above method may be used to select antisense molecules capable of deleting any exon from within a protein that is capable of being shortened without affecting its biological function, the exon deletion should not lead to a reading frame shift in the shortened transcribed mRNA. Thus, if in a linear sequence of three exons the end of the first exon encodes two of three nucleotides in a codon and the next exon is deleted then the third exon in the linear sequence must start with a single nucleotide that is capable of completing the nucleotide triplet for a codon. If the third exon does not commence with a single nucleotide there will be a reading frame shift that would lead to the generation of truncated or a non-functional protein.
  • It will be appreciated that the codon arrangements at the end of exons in structural proteins may not always break at the end of a codon, consequently there may be a need to delete more than one exon from the pre-mRNA to ensure in-frame reading of the mRNA. In such circumstances, a plurality of antisense oligonucleotides may need to be selected by the method of the invention wherein each is directed to a different region responsible for inducing splicing in the exons that are to be deleted.
  • The length of an antisense molecule may vary so long as it is capable of binding selectively to the intended location within the pre-mRNA molecule. The length of such sequences can be determined in accordance with selection procedures described herein. Generally, the antisense molecule will be from about 10 nucleotides in length up to about 50 nucleotides in length. It will be appreciated however that any length of nucleotides within this range may be used in the method. Preferably, the length of the antisense molecule is between 17 to 30 nucleotides in length.
  • In order to determine which exons can be connected in a dystrophin gene, reference should be made to an exon boundary map. Connection of one exon with another is based on the exons possessing the same number at the 3′ border as is present at the 5′ border of the exon to which it is being connected. Therefore, if exon 7 were deleted, exon 6 must connect to either exons 12 or 18 to maintain the reading frame. Thus, antisense oligonucleotides would need to be selected which redirected splicing for exons 7 to 11 in the first instance or exons 7 to 17 in the second instance. Another and somewhat simpler approach to restore the reading frame around an exon 7 deletion would be to remove the two flanking exons. Induction of exons 6 and 8 skipping should result in an in-frame transcript with the splicing of exons 5 to 9. In practise however, targeting exon 8 for removal from the pre-mRNA results in the co-removal of exon 9 so the resultant transcript would have exon 5 joined to exon 10. The inclusion or exclusion of exon 9 does not alter the reading frame. Once the antisense molecules to be tested have been identified, they are prepared according to standard techniques known in the art. The most common method for producing antisense molecules is the methylation of the 2′ hydroxyribose position and the incorporation of a phosphorothioate backbone produces molecules that superficially resemble RNA but that are much more resistant to nuclease degradation.
  • To avoid degradation of pre-mRNA during duplex formation with the antisense molecules, the antisense molecules used in the method may be adapted to minimise or prevent cleavage by endogenous RNase H. This property is highly preferred as the treatment of the RNA with the unmethylated oligonucleotides either intracellularly or in crude extracts that contain RNase H leads to degradation of the pre-mRNA: antisense oligonucleotide duplexes. Any form of modified antisense molecules that is capable of by-passing or not inducing such degradation may be used in the present method. An example of antisense molecules which when duplexed with RNA are not cleaved by cellular RNase H is 2′-O-methyl derivatives. 2′-O-methyl-oligoribonucleotides are very stable in a cellular environment and in animal tissues, and their duplexes with RNA have higher Tm values than their ribo- or deoxyribo-counterparts.
  • Antisense molecules that do not activate RNase H can be made in accordance with known techniques (see, e.g., U.S. Pat. No. 5,149,797). Such antisense molecules, which may be deoxyribonucleotide or ribonucleotide sequences, simply contain any structural modification which sterically hinders or prevents binding of RNase H to a duplex molecule containing the oligonucleotide as one member thereof, which structural modification does not substantially hinder or disrupt duplex formation. Because the portions of the oligonucleotide involved in duplex formation are substantially different from those portions involved in RNase H binding thereto, numerous antisense molecules that do not activate RNase H are available. For example, such antisense molecules may be oligonucleotides wherein at least one, or all, of the inter-nucleotide bridging phosphate residues are modified phosphates, such as methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates and phosphoramidates. For example, every other one of the internucleotide bridging phosphate residues may be modified as described. In another non-limiting example, such antisense molecules are molecules wherein at least one, or all, of the nucleotides contain a 2′ lower alkyl moiety (e.g., C1-C4, linear or branched, saturated or unsaturated alkyl, such as methyl, ethyl, ethenyl, propyl, 1-propenyl, 2-propenyl, and isopropyl). For example, every other one of the nucleotides may be modified as described.
  • While antisense oligonucleotides are a preferred form of the antisense molecules, the present invention comprehends other oligomeric antisense molecules, including but not limited to oligonucleotide mimetics such as are described below.
  • Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural inter-nucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their inter-nucleoside backbone can also be considered to be oligonucleosides.
  • In other preferred oligonucleotide mimetics, both the sugar and the inter-nucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleo-bases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
  • Modified oligonucleotides may also contain one or more substituted sugar moieties. Oligonucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. Certain nucleo-bases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. and are presently preferred base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.
  • Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety.
  • It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds that are chimeric compounds. “Chimeric” antisense compounds or “chimeras,” in the context of this invention, are antisense molecules, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the increased resistance to nuclease degradation, increased cellular uptake, and an additional region for increased binding affinity for the target nucleic acid.
  • Methods of Manufacturing Antisense Molecules
  • The antisense molecules used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). One method for synthesising oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066.
  • Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives. In one such automated embodiment, diethyl-phosphoramidites are used as starting materials and may be synthesized as described by Beaucage, et al., (1981) Tetrahedron Letters, 22:1859-1862.
  • The antisense molecules of the invention are synthesised in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The molecules of the invention may also be mixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.
  • Therapeutic Agents
  • The present invention also can be used as a prophylactic or therapeutic, which may be utilised for the purpose of treatment of a genetic disease.
  • Accordingly, in one embodiment the present invention provides antisense molecules that bind to a selected target in the dystrophin pre-mRNA to induce efficient and consistent exon skipping described herein in a therapeutically effective amount admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
  • The phrase “pharmaceutically acceptable” refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similarly untoward reaction, such as gastric upset and the like, when administered to a patient. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in Martin, Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, Pa., (1990).
  • In a more specific form of the invention there are provided pharmaceutical compositions comprising therapeutically effective amounts of an antisense molecule together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength and additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). The material may be incorporated into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc. or into liposomes. Hylauronic acid may also be used. Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the present proteins and derivatives. See, e.g., Martin, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712 that are herein incorporated by reference. The compositions may be prepared in liquid form, or may be in dried powder, such as lyophilised form.
  • It will be appreciated that pharmaceutical compositions provided according to the present invention may be administered by any means known in the art. Preferably, the pharmaceutical compositions for administration are administered by injection, orally, or by the pulmonary, or nasal route. The antisense molecules are more preferably delivered by intravenous, intra-arterial, intraperitoneal, intramuscular, or subcutaneous routes of administration.
  • Antisense Molecule Based Therapy
  • Also addressed by the present invention is the use of antisense molecules of the present invention, for manufacture of a medicament for modulation of a genetic disease.
  • The delivery of a therapeutically useful amount of antisense molecules may be achieved by methods previously published. For example, intracellular delivery of the antisense molecule may be via a composition comprising an admixture of the antisense molecule and an effective amount of a block copolymer. An example of this method is described in US patent application US 20040248833.
  • Other methods of delivery of antisense molecules to the nucleus are described in Mann C J et al., (2001) [“Antisense-induced exon skipping and the synthesis of dystrophin in the mdx mouse”. Proc., Natl. Acad. Science, 98(1) 42-47] and in Gebski et al., (2003). Human Molecular Genetics, 12(15): 1801-1811.
  • A method for introducing a nucleic acid molecule into a cell by way of an expression vector either as naked DNA or complexed to lipid carriers, is described in U.S. Pat. No. 6,806,084.
  • It may be desirable to deliver the antisense molecule in a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes or liposome formulations.
  • Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. These formulations may have net cationic, anionic or neutral charge characteristics and are useful characteristics with in vitro, in vivo and ex vivo delivery methods. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0.PHI.m can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, and DNA can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981).
  • In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the antisense molecule of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).
  • The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
  • Alternatively, the antisense construct may be combined with other pharmaceutically acceptable carriers or diluents to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral or transdermal administration.
  • The routes of administration described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and any dosage for any particular animal and condition. Multiple approaches for introducing functional new genetic material into cells, both in vitro and in vivo have been attempted (Friedmann (1989) Science, 244:1275-1280).
  • These approaches include integration of the gene to be expressed into modified retroviruses (Friedmann (1989) supra; Rosenberg (1991) Cancer Research 51(18), suppl.: 5074S-5079S); integration into non-retrovirus vectors (Rosenfeld, et al. (1992) Cell, 68:143-155; Rosenfeld, et al. (1991) Science, 252:431-434); or delivery of a transgene linked to a heterologous promoter-enhancer element via liposomes (Friedmann (1989), supra; Brigham, et al. (1989) Am. J. Med. Sci., 298:278-281; Nabel, et al. (1990) Science, 249:1285-1288; Hazinski, et al. (1991) Am. J. Resp. Cell Molec. Biol., 4:206-209; and Wang and Huang (1987) Proc. Natl. Acad. Sci. (USA), 84:7851-7855); coupled to ligand-specific, cation-based transport systems (Wu and Wu (1988) J. Biol. Chem., 263:14621-14624) or the use of naked DNA, expression vectors (Nabel et al. (1990), supra); Wolff et al. (1990) Science, 247:1465-1468). Direct injection of transgenes into tissue produces only localized expression (Rosenfeld (1992) supra); Rosenfeld et al. (1991) supra; Brigham et al. (1989) supra; Nabel (1990) supra; and Hazinski et al. (1991) supra). The Brigham et al. group (Am. J. Med. Sci. (1989) 298:278-281 and Clinical Research (1991) 39 (abstract)) have reported in vivo transfection only of lungs of mice following either intravenous or intratracheal administration of a DNA liposome complex. An example of a review article of human gene therapy procedures is: Anderson, Science (1992) 256:808-813.
  • The antisense molecules of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such pro-drugs, and other bioequivalents.
  • The term “pharmaceutically acceptable salts” refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.
  • For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, (including by nebulizer, intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2′-O-methoxyethyl modification are believed to be particularly useful for oral administration.
  • The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • Kits of the Invention
  • The invention also provides kits for treatment of a patient with a genetic disease which kit comprises at least an antisense molecule, packaged in a suitable container, together with instructions for its use.
  • In a preferred embodiment, the kits will contain at least one antisense molecule as shown in Table 1A, or a cocktail of antisense molecules as shown in Table 1B or a “weasel” compound as shown in Table 1C. The kits may also contain peripheral reagents such as buffers, stabilizers, etc.
  • Those of ordinary skill in the field should appreciate that applications of the above method has wide application for identifying antisense molecules suitable for use in the treatment of many other diseases.
  • EXAMPLES
  • The following Examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these Examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. The references cited herein are expressly incorporated by reference.
  • Methods of molecular cloning, immunology and protein chemistry, which are not explicitly described in the following examples, are reported in the literature and are known by those skilled in the art. General texts that described conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art, included, for example: Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Glover ed., DNA Cloning: A Practical Approach, Volumes I and II, MRL Press, Ltd., Oxford, U.K. (1985); and Ausubel, F., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., Struhl, K. Current Protocols in Molecular Biology. Greene Publishing Associates/Wiley Intersciences, New York (2002).
  • Determining Induced Exon Skipping in Human Muscle Cells
  • Attempts by the inventors to develop a rational approach in antisense molecules design were not completely successful as there did not appear to be a consistent trend that could be applied to all exons. As such, the identification of the most effective and therefore most therapeutic antisense molecules compounds has been the result of empirical studies.
  • These empirical studies involved the use of computer programs to identify motifs potentially involved in the splicing process. Other computer programs were also used to identify regions of the pre-mRNA which may not have had extensive secondary structure and therefore potential sites for annealing of antisense molecules. Neither of these approaches proved completely reliable in designing antisense oligonucleotides for reliable and efficient induction of exon skipping.
  • Annealing sites on the human dystrophin pre-mRNA were selected for examination, initially based upon known or predicted motifs or regions involved in splicing. 2OMe antisense oligonucleotides were designed to be complementary to the target sequences under investigation and were synthesised on an Expedite 8909 Nucleic Acid Synthesiser. Upon completion of synthesis, the oligonucleotides were cleaved from the support column and de-protected in ammonium hydroxide before being desalted. The quality of the oligonucleotide synthesis was monitored by the intensity of the trityl signals upon each deprotection step during the synthesis as detected in the synthesis log. The concentration of the antisense oligonucleotide was estimated by measuring the absorbance of a diluted aliquot at 260 nm.
  • Specified amounts of the antisense molecules were then tested for their ability to induce exon skipping in an in vitro assay, as described below.
  • Briefly, normal primary myoblast cultures were prepared from human muscle biopsies obtained after informed consent. The cells were propagated and allowed to differentiate into myotubes using standard culturing techniques. The cells were then transfected with the antisense oligonucleotides by delivery of the oligonucleotides to the cells as cationic lipoplexes, mixtures of antisense molecules or cationic liposome preparations.
  • The cells were then allowed to grow for another 24 hours, after which total RNA was extracted and molecular analysis commenced. Reverse transcriptase amplification (RT-PCR) was undertaken to study the targeted regions of the dystrophin pre-mRNA or induced exonic re-arrangements.
  • For example, in the testing of an antisense molecule for inducing exon 19 skipping the RT-PCR test scanned several exons to detect involvement of any adjacent exons. For example, when inducing skipping of exon 19, RT-PCR was carried out with primers that amplified across exons 17 and 21. Amplifications of even larger products in this area (i.e. exons 13-26) were also carried out to ensure that there was minimal amplification bias for the shorter induced skipped transcript. Shorter or exon skipped products tend to be amplified more efficiently and may bias the estimated of the normal and induced transcript.
  • The sizes of the amplification reaction products were estimated on an agarose gel and compared against appropriate size standards. The final confirmation of identity of these products was carried out by direct DNA sequencing to establish that the correct or expected exon junctions have been maintained.
  • Once efficient exon skipping had been induced with one antisense molecule, subsequent overlapping antisense molecules may be synthesized and then evaluated in the assay as described above. Our definition of an efficient antisense molecule is one that induces strong and sustained exon skipping at transfection concentrations in the order of 300 nM or less.
  • Antisense Oligonucleotides Directed at Exon 8
  • Antisense oligonucleotides directed at exon 8 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 3 shows differing efficiencies of two antisense molecules directed at exon 8 acceptor splice site. H8A(−06+18) [SEQ ID NO:1], which anneals to the last 6 bases of intron 7 and the first 18 bases of exon 8, induces substantial exon 8 and 9 skipping when delivered into cells at a concentration of 20 nM. The shorter antisense molecule, H8A(−06+14) [SEQ ID NO: 4] was only able to induce exon 8 and 9 skipping at 300 nM, a concentration some 15 fold higher than H8A(−06+18), which is the preferred antisense molecule.
  • This data shows that some particular antisense molecules induce efficient exon skipping while another antisense molecule, which targets a near-by or overlapping region, can be much less efficient. Titration studies show one compound is able to induce targeted exon skipping at 20 nM while the less efficient antisense molecules only induced exon skipping at concentrations of 300 nM and above. Therefore, we have shown that targeting of the antisense molecules to motifs involved in the splicing process plays a crucial role in the overall efficacy of that compound.
  • Efficacy refers to the ability to induce consistent skipping of a target exon. However, sometimes skipping of the target exons is consistently associated with a flanking exon. That is, we have found that the splicing of some exons is tightly linked. For example, in targeting exon 23 in the mouse model of muscular dystrophy with antisense molecules directed at the donor site of that exon, dystrophin transcripts missing exons 22 and 23 are frequently detected. As another example, when using an antisense molecule directed to exon 8 of the human dystrophin gene, all induced transcripts are missing both exons 8 and 9. Dystrophin transcripts missing only exon 8 are not observed.
  • Table 2 below discloses antisense molecule sequences that induce exon 8 (and 9) skipping.
  • TABLE 2
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H8A(−06 +18) 5′- GAU AGG UGG UAU CAA CAU CUG UAA Very strong to
     20 nM
    H8A (−03 +18) 5′- GAU AGG UGG UAU CAA CAU CUG Very strong
    skipping to
     40 nM
    H8A(−07 +18) 5′- GAU AGG UGG UAU CAA CAU CUG UAA G Strong
    skipping to
     40 nM
    H8A(−06 +14) 5′- GGU GGU AUC AAC AUC UGU AA Skipping to
    300 nM
    H8A(−10 +10) 5′- GUA UCA ACA UCU GUA AGC AC Patchy/weak
    skipping to
    100 nm
  • Antisense Oligonucleotides Directed at Exon 7
  • Antisense oligonucleotides directed at exon 7 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 4 shows the preferred antisense molecule, H7A(+45+67) [SEQ ID NO: 6], and another antisense molecule, H7A(+2+26) [SEQ ID NO: 7], inducing exon 7 skipping. Nested amplification products span exons 3 to 9. Additional products above the induced transcript missing exon 7 arise from amplification from carry-over outer primers from the RT-PCR as well as heteroduplex formation.
  • Table 3 below discloses antisense molecule sequences for induced exon 7 skipping.
  • TABLE 3
    Antisense
    Oligonucleotide Ability to induce
    name Sequence skipping
    H7A(+45 +67) 5′- UGC AUG UUC CAG UCG UUG UGU GG Strong skipping to
     20 nM
    H7A(+02 +26) 5′- CAC UAU UCC AGU CAA AUA GGU CUG G Weak skipping at
    100 nM
    H7D(+15 −10) 5′- AUU UAC CAA CCU UCA GGA UCG AGU A Weak skipping to
    300 nM
    H7A(−18 +03) 5′- GGC CUA AAA CAC AUA CAC AUA Weak skipping to
    300 nM
  • Antisense Oligonucleotides Directed at Exon 6
  • Antisense oligonucleotides directed at exon 6 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 5 shows an example of two non-preferred antisense molecules inducing very low levels of exon 6 skipping in cultured human cells. Targeting this exon for specific removal was first undertaken during a study of the canine model using the oligonucleotides as listed in Table 4, below. Some of the human specific oligonucleotides were also evaluated, as shown in FIG. 5. In this example, both antisense molecules target the donor splice site and only induced low levels of exon 6 skipping. Both H6D(+4−21) [SEQ ID NO: 17] and H6D(+18−4) [SEQ ID NO: 18] would be regarded as non-preferred antisense molecules.
  • One antisense oligonucleotide that induced very efficient exon 6 skipping in the canine model, C6A(+69+91) [SEQ ID NO: 14], would anneal perfectly to the corresponding region in human dystrophin exon 6. This compound was evaluated, found to be highly efficient at inducing skipping of that target exon, as shown in FIG. 6 and is regarded as the preferred compound for induced exon 6 skipping. Table 4 below discloses antisense molecule sequences for induced exon 6 skipping.
  • TABLE 4
    Antisense Ability
    Oligo to induce
    name Sequence skipping
    C6A(-10 +10) 5′ CAU UUU UGA CCU ACA UGU GG No skipping
    C6A(-14 +06) 5′ UUU GAC CUA CAU GUG GAA AG No skipping
    C6A(-14 +12) 5′ UAC AUU UUU GAC CUA CAU GUG No skipping
    GAA AG
    C6A(-13 +09) 5′ AUU UUU GAC CUA CAU GGG AAA G No skipping
    CH6A(+69 +91) 5′ UAC GAG UUG AUU GUC GGA CCC Strong
    AG skipping to
     20 nM
    C6D(+12 −13) 5′ GUG GUC UCC UUA CCU AUG ACU Weak
    GUG G skipping at
    300 nM
    C6D(+06 −11) 5′ GGU CUC CUU ACC UAU GA No skipping
    H6D(+04 −21) 5′ UGU CUC AGU AAU CUU CUU ACC Weak
    UAU skipping to
     50 nM
    H6D(+18 −04) 5′ UCU UAC CUA UGA CUA UGG AUG Very weak
    AGA skipping to
    300 nM
  • Antisense Oligonucleotides Directed at Exon 4
  • Antisense oligonucleotides directed at exon 4 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 7 shows an example of a preferred antisense molecule inducing skipping of exon 4 skipping in cultured human cells. In this example, one preferred antisense compound, H4A(+13+32) [SEQ ID NO:19], which targeted a presumed exonic splicing enhancer induced efficient exon skipping at a concentration of 20 nM while other non-preferred antisense oligonucleotides failed to induce even low levels of exon 4 skipping. Another preferred antisense molecule inducing skipping of exon 4 was H4A(+111+40) [SEQ ID NO:22], which induced efficient exon skipping at a concentration of 20 nM.
  • Table 5 below discloses antisense molecule sequences for inducing exon 4 skipping.
  • TABLE 5
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H4A(+13 +32) 5′ GCA UGA ACU CUU GUG GAU CC Skipping to
    20 nM
    H4A(+11 +40) 5′ UGU UCA GGG CAU GAA CUC UUG UGG AUC Skipping to
    CUU 20 nM
    H4D(+04 −16) 5′ CCA GGG UAC UAC UUA CAU UA No skipping
    H4D(−24 −44) 5′ AUC GUG UGU CAC AGC AUC CAG No skipping
  • Antisense Oligonucleotides Directed at Exon 3
  • Antisense oligonucleotides directed at exon 3 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H3A(+30+60) [SEQ ID NO:23] induced substantial exon 3 skipping when delivered into cells at a concentration of 20 nM to 600 nM. The antisense molecule, H3A(+35+65) [SEQ ID NO: 24] induced exon skipping at 300 nM.
  • Table 6 below discloses antisense molecule sequences that induce exon 3 skipping.
  • TABLE 6
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H3A(+30 +60) UAG GAG GCG CCU CCC AUC CUG UAG GUC Moderate
    ACU G skipping to
     20 to 600 nM
    H3A(+35 +65) AGG UCU AGG AGG CGC CUC CCA UCC UGU Working to
    AGG U 300 nM
    H3A(+30 +54) GCG CCU CCC AUC CUG UAG GUC ACU G Moderate
    100-600 nM
    H3D(+46 −21) CUU CGA GGA GGU CUA GGA GGC GCC UC No skipping
    H3A(+30 +50) CUC CCA UCC UGU AGG UCA CUG Moderate
     20-600 nM
    H3D(+19 −03) UAC CAG UUU UUG CCC UGU CAG G No skipping
    H3A(−06 +20) UCA AUA UGC UGC UUCCCA AAC UGA AA No skipping
    H3A(+37 +61) CUA GGA GGC GCC UCC CAU CCU GUA G No skipping
  • Antisense Oligonucleotides Directed at Exon 5
  • Antisense oligonucleotides directed at exon 5 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H5A(+20+50) [SEQ ID NO:31] induces substantial exon 5 skipping when delivered into cells at a concentration of 100 nM. Table 7 below shows other antisense molecules tested. The majority of these antisense molecules were not as effective at exon skipping as H5A(+20+50). However, H5A(+15+45) [SEQ ID NO: 40] was able to induce exon 5 skipping at 300 nM.
  • Table 7 below discloses antisense molecule sequences that induce exon 5 skipping.
  • TABLE 7
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H5A(+20 +50) UUA UGA UUU CCA UCU ACG AUG UCA GUA Working to
    CUU C 100 nM
    H5D(+25 −05) CUU ACC UGC CAG UGG AGG AUU AUA UUC No skipping
    CAA A
    H5D(+10 −15) CAU CAG GAU UCU UAC CUG CCA GUG G Inconsistent at
    300 nM
    H5A(+10 +34) CGA UGU CAG UAC UUC CAA UAU UCA C Very weak
    H5D(−04 −21) ACC AUU CAU CAG GAU UCU No skipping
    H5D(+16 −02) ACC UGC CAG UGG AGG AUU No skipping
    H5A(−07 +20) CCA AUA UUC ACU AAA UCA ACC UGU UAA No skipping
    H5D(+18 −12) CAG GAU UCU UAC CUG CCA GUG GAG GAU No skipping
    UAU
    H5A(+05 +35) ACG AUG UCA GUA CUU CCA AUA UUC ACU No skipping
    AAA U
    H5A(+15 +45) AUU UCC AUC UAC GAU GUC AGU ACU UCC Working to
    AAU A 300 nM
  • Antisense Oligonucleotides Directed at Exon 10
  • Antisense oligonucleotides directed at exon 10 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H10A(−05+16) [SEQ ID NO:41] induced substantial exon 10 skipping when delivered into cells. Table 8 below shows other antisense molecules tested. The antisense molecules ability to induce exon skipping was variable. Table 8 below discloses antisense molecule sequences that induce exon 10 skipping.
  • TABLE 8
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H10A(−05 +16) CAG GAG CUU CCA AAU GCU GCA Not tested
    H10A(−05 +24) CUU GUC UUC AGG AGC UUC CAA AUG CUG Not tested
    CA
    H10A(+98 +119) UCC UCA GCA GAA AGA AGC CAC G Not tested
    H10A(+130 +149) UUA GAA AUC UCU CCU UGU GC No skipping
    H10A(−33 −14) UAA AUU GGG UGU UAC ACA AU No skipping
  • Antisense Oligonucleotides Directed at Exon 11
  • Antisense oligonucleotides directed at exon 11 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 8B shows an example of H11A(+75+97) [SEQ ID NO:49] antisense molecule inducing exon 11 skipping in cultured human cells. H11A(+75+97) induced substantial exon 11 skipping when delivered into cells at a concentration of 5 nM. Table 9 below shows other antisense molecules tested. The antisense molecules ability to induce exon skipping was observed at 100 nM.
  • TABLE 9
    Antisense Ability to
    Oligonucleotide induce
    name Sequence skipping
    H11D(+26 +49) CCC UGA GGC AUU CCC AUC UUG AAU Skipping at
    100 nM
    H11 D(+11 −09) AGG ACU UAC UUG CUU UGU UU Skipping at
    100 nM
    H11A(+118 +140) CUU GAA UUU AGG AGA UUC AUC UG Skipping at
    100 nM
    H11A(+75 +97) CAU CUU CUG AUA AUU UUC CUG UU Skipping at
    100 nM
    H11D(+26 +49) CCC UGA GGC AUU CCC AUC UUG AAU Skipping at
      5 nM
  • Antisense Oligonucleotides Directed at Exon 12
  • Antisense oligonucleotides directed at exon 12 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H12A(+52+75) [SEQ ID NO:50] induced substantial exon 12 skipping when delivered into cells at a concentration of 5 nM, as shown in FIG. 8A. Table 10 below shows other antisense molecules tested at a concentration range of 5, 25, 50, 100, 200 and 300 nM. The antisense molecules ability to induce exon skipping was variable.
  • TABLE 10
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H12A UCU UCU GUU UUU GUU AGC Skipping at
    (+52+75) CAG UCA 5 nM
    H12A UCU AUG UAA ACU GAA AAU Skipping at
    (−10+10) UU 100 nM
    H12A UUC UGG AGA UCC AUU AAA No skipping
    (+11+30) AC
  • Antisense Oligonucleotides Directed at Exon 13
  • Antisense oligonucleotides directed at exon 13 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H13A(+77+100) [SEQ ID NO:53] induced substantial exon 13 skipping when delivered into cells at a concentration of 5 nM. Table 11 below includes two other antisense molecules tested at a concentration range of 5, 25, 50, 100, 200 and 300 nM. These other antisense molecules were unable to induce exon skipping.
  • TABLE 11
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H13A CAG CAG UUG CGU GAU CUC Skipping at
    (+77+100) CAC UAG 5 nM
    H13A UUC AUC AAC UAC CAC CAC No skipping
    (+55+75) CAU
    H13D CUA AGC AAA AUA AUC UGA No skipping
    (+06−19) CCU UAA G
  • Antisense Oligonucleotides Directed at Exon 14
  • Antisense oligonucleotides directed at exon 14 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H14A(+37+64) [SEQ ID NO:56] induced weak exon 14 skipping when delivered into cells at a concentration of 100 nM. Table 12 below includes other antisense molecules tested at a concentration range of 5, 25, 50, 100, 200 and 300 nM. The other antisense molecules were unable to induce exon skipping at any of the concentrations tested.
  • TABLE 12
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H14A CUU GUA AAA GAA CCC AGC Skipping at
    (+37+64) GGU CUU CUG U 100 nM
    H14A CAU CUA CAG AUG UUU GCC No skipping
    (+14+35) CAU C
    H14A GAA GGA UGU CUU GUA AAA No skipping
    (+51+73) GAA CC
    H14D ACC UGU UCU UCA GUA AGA CG No skipping
    (−02+18)
    H14D CAU GAC ACA CCU GUU CUU No skipping
    (+14−10) CAG UAA
    H14A CAU UUG AGA AGG AUG UCU UG No skipping
    (+61+80)
    H14A AUC UCC CAA UAC CUG GAG No skipping
    (−12+12) AAG AGA
  • Antisense Oligonucleotides Directed at Exon 15
  • Antisense oligonucleotides directed at exon 15 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H15A(−12+19) [SEQ ID NO:63] and H15A(+48+71) [SEQ ID NO:64] induced substantial exon 15 skipping when delivered into cells at a concentration of 10 Nm, as shown in FIG. 9A. Table 13 below includes other antisense molecules tested at a concentration range of 5, 25, 50, 100, 200 and 300 Nm. These other antisense molecules were unable to induce exon skipping at any of the concentrations tested.
  • TABLE 13
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H15A GCC AUG CAC UAA AAA GGC Skipping at
    (−12+19) ACU GCA AGA CAU U 5 Nm
    H15A UCU UUA AAG CCA GUU GUG Skipping at
    (+48+71) UGA AUC 5 Nm
    H15A UUU CUG AAA GCC AUG CAC No skipping
    (+08+28) UAA
    H15A GCC AUG CAC UAA AAA GGC No skipping
    (−12+19) ACU GCA AGA CAU U
    H15D GUA CAU ACG GCC AGU UUU No skipping
    (+17−08) UGA AGA C
  • Antisense Oligonucleotides Directed at Exon 16
  • Antisense oligonucleotides directed at exon 16 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H16A(−12+19) [SEQ ID NO:67] and H16A(−06+25) [SEQ ID NO:68] induced substantial exon 16 skipping when delivered into cells at a concentration of 10 nM, as shown in FIG. 9B. Table 14 below includes other antisense molecules tested. H16A(−06+19) [SEQ ID NO:69] and H16A(+87+109) [SEQ ID NO:70] were tested at a concentration range of 5, 25, 50, 100, 200 and 300 nM. These two antisense molecules were able to induce exon skipping at 25 nM and 100 nM, respectively. Additional antisense molecules were tested at 100, 200 and 300 nM and did not result in any exon skipping.
  • TABLE 14
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H16A CUA GAU CCG CUU UUA AAA Skipping at
    (−12+19) CCU GUU AAA ACA A 5 nM
    H16A UCU UUU CUA GAU CCG CUU Skipping at
    (−06+25) UUA AAA CCU GUU A 5 nM
    H16A CUA GAU CCG CUU UUA AAA Skipping at
    (−06+19) CCU GUU A 25 nM
    H16A CCG UCU UCU GGG UCA CUG Skipping at
    (+87+109) ACU UA 100 nM
    H16A CUA GAU CCG CUU UUA AAA No skipping
    (−07+19) CCU GUU AA
    H16A CCG CUU UUA AAA CCU GUU AA No skipping
    (−07+13)
    H16A UGG AUU GCU UUU UCU UUU No skipping
    (+12+37) CUA GAU CC
    H16A CAU GCU UCC GUC UUC UGG No skipping
    (+92+116) GUC ACU G
    H16A G AUC UUG UUU GAG UGA AUA No skipping
    (+45+67) CAG U
    H16A GUU AUC CAG CCA UGC UUC No skipping
    (+105+126) CGU C
    H16D UGA UAA UUG GUA UCA CUA No skipping
    (+05−20) ACC UGU G
    H16D GUA UCA CUA ACC UGU GCU No skipping
    (+12−11) GUA C
  • Antisense Oligonucleotides Directed at Exon 19
  • Antisense oligonucleotides directed at exon 19 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H19A(+35+65) [SEQ ID NO:79] induced substantial exon 19 skipping when delivered into cells at a concentration of 10 nM. This antisense molecule also showed very strong exon skipping at concentrations of 25, 50, 100, 300 and 600 nM.
  • FIG. 10 illustrates exon 19 and 20 skipping using a “cocktail” of antisense oligonucleotides, as tested using gel electrophoresis. It is interesting to note that it was not easy to induce exon 20 skipping using single antisense oligonucleotides H20A(+44+71) [SEQ ID NO:81] or H20A(+149+170) [SEQ ID NO:82], as illustrated in sections 2 and 3 of the gel shown in FIG. 10. Whereas, a “cocktail” of antisense oligonucleotides was more efficient as can be seen in section 4 of FIG. 10 using a “cocktail” of antisense oligonucleotides H20A(+44+71) and H20A(+149+170). When the cocktail was used to target exon 19, skipping was even stronger (see section 5, FIG. 10).
  • FIG. 11 illustrates gel electrophoresis results of exon 19/20 skipping using “weasels” The “weasels” were effective in skipping exons 19 and 20 at concentrations of 25, 50, 100, 300 and 600 nM. A further “weasel” sequence is shown in the last row of Table 3C. This compound should give good results.
  • Antisense Oligonucleotides Directed at Exon 20
  • Antisense oligonucleotides directed at exon 20 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • None of the antisense oligonucleotides tested induced exon 20 skipping when delivered into cells at a concentration of 10, 25, 50, 300 or 600 nM (see Table 15). Antisense molecules H20A(−11+17) [SEQ ID NO:86] and H20D(+08−20) [SEQ ID NO:87] are yet to be tested.
  • However, a combination or “cocktail” of H20A(+44+71) [SEQ ID NO: 81] and H20(+149+170) [SEQ ID NO:82] in a ratio of 1:1, exhibited very strong exon skipping at a concentration of 100 nM and 600 nM. Further, a combination of antisense molecules H19A(+35+65) [SEQ ID NO:79], H20A(+44+71) [SEQ ID NO:81] and H20A(+149+170) [SEQ ID NO:82] in a ratio of 2:1:1, induced very strong exon skipping at a concentration ranging from 10 nM to 600 nM.
  • TABLE 15
    Antisense
    Oligo- Ability to
    nucloetide induce
    name Sequence skipping
    H20A CUG GCA GAA UUC GAU CCA No skipping
    (+44+71) CCG GCU GUU C
    H20A CAG CAG UAG UUG UCA UCU No skipping
    (+149+170) GCU C
    H20A UGA UGG GGU GGU GGG UUG No skipping
    (+185+203) G
    H20A AUC UGC AUU AAC ACC CUC No skipping
    (−08+17) UAG AAA G
    H20A CCG GCU GUU CAG UUG UUC No skipping
    (+30+53) UGA GGC
    H20A AUC UGC AUU AAC ACC CUC Not tested
    (−11+17) UAG AAA GAA A yet
    H20D GAA GGA GAA GAG AUU CUU Not tested
    (+08−20) ACC UUA CAA A yet
    H20A CUG GCA GAA UUC GAU CCA Very strong
    (+44+71) & CCG GCU GUU C skipping
    H20A CAG CAG UAG UUG UCA UCU
    (+149+170) GCU C
    H19A GCC UGA GCU GAU CUG CUG Very strong
    (+44+71): GCA UCU UGC AGU U skipping
    H20A CUG GCA GAA UUC GAU CCA
    (+44+71); CCG GCU GUU C
    H20A CAG CAG UAG UUG UCA UCU
    (+149+170) GCU C
  • Antisense Oligonucleotides Directed at Exon 21
  • Antisense oligonucleotides directed at exon 21 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H21A(+85+108) [SEQ ID NO:92] and H21A(+85+106) [SEQ ID NO:91] induced exon 21 skipping when delivered into cells at a concentration of 50 nM. Table 16 below includes other antisense molecules tested at a concentration range of 5, 25, 50, 100, 200 and 300 nM. These antisense molecules showed a variable ability to induce exon skipping
  • TABLE 16
    Antisense
    Oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H21A GCC GGU UGA CUU CAU CCU Skips at
    (−06+16) GUG C 600 nM
    H21A CUG CAU CCA GGA ACA UGG Skips at 50
    (+85+106) GUC C nM
    H21A GUC UGC AUC CAG GAA CAU Skips at 50
    (+85+108) GGG UC nM
    H21A GUU GAA GAU CUG AUA GCC Skips
    (+08+31) GGU UGA faintly to
    H21D UAC UUA CUG UCU GUA GCU No skipping
    (+18−07) CUU UCU
  • Antisense Oligonucleotides Directed at Exon 22
  • Antisense oligonucleotides directed at exon 22 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 12 illustrates differing efficiencies of two antisense molecules directed at exon 22 acceptor splice site. H22A(+125+106) [SEQ ID NO:96] and H22A(+80+101) [SEQ ID NO: 98] induce strong exon 22 skipping from 50 nM to 600 nM concentration.
  • H22A(+125+146) [SEQ ID NO:96] and H22A(+80+101) [SEQ ID NO:98] induced exon 22 skipping when delivered into cells at a concentration of 50 nM. Table 17 below shows other antisense molecules tested at a concentration range of 50, 100, 300 and 600 nM. These antisense molecules showed a variable ability to induce exon skipping.
  • TABLE 17
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H22A CAC UCA UGG UCU CCU GAU No skipping
    (+22+45) AGC GCA
    H22A CUG CAA UUC CCC GAG UCU Skipping to
    (+125+146) CUG C 50 nM
    H22A ACU GCU GGA CCC AUG UCC Skipping to
    (+47+69) UGA UG 300 nM
    H22A CUA AGU UGA GGU AUG GAG Skipping to
    (+80+101) AGU 50 nM
    H22D UAU UCA CAG ACC UGC AAU No skipping
    (+13−11)  UCC CC
  • Antisense Oligonucleotides Directed at Exon 23
  • Antisense oligonucleotides directed at exon 23 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • Table 18 below shows antisense molecules tested at a concentration range of 25, 50, 100, 300 and 600 nM. These antisense molecules showed no ability to induce exon skipping or are yet to be tested.
  • TABLE 18
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H23A ACA GUG GUG CUG AGA UAG No skipping
    (+34+59) UAU AGG CC
    H23A UAG GCC ACU UUG UUG CUC No Skipping
    (+18+39) UUG C
    H23A UUC AGA GGG CGC UUU CUU C No Skipping
    (+72+90)
  • Antisense Oligonucleotides Directed at Exon 24
  • Antisense oligonucleotides directed at exon 24 were prepared using similar methods as described above. Table 19 below outlines the antisense oligonucleotides directed at exon 24 that are yet to be tested for their ability to induce exon 24 skipping.
  • TABLE 19
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H24A GGG CAG GCC AUU CCU CCU UCA Needs
    (+48+70) GA testing
    H24A UCU UCA GGG UUU GUA UGU GAU Needs
    (−02+22) UCU testing
  • Antisense Oligonucleotides Directed at Exon 25
  • Antisense oligonucleotides directed at exon 25 were prepared using similar methods as described above. Table 20 below shows the antisense oligonucleotides directed at exon 25 that are yet to be tested for their ability to induce exon 25 skipping.
  • TABLE 20
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H25A CUG GGC UGA AUU GUC UGA AUA Needs
    (+9+36) UCA CUG testing
    H25A CUG UUG GCA CAU GUG AUC CCA Needs
    (+131+156) CUG AG testing
    H25D GUC UAU ACC UGU UGG CAC AUG Needs
    (+16−08) UGA testing
  • Antisense Oligonucleotides Directed at Exon 26
  • Antisense oligonucleotides directed at exon 26 were prepared using similar methods as described above. Table 21 below outlines the antisense oligonucleotides directed at exon 26 that are yet to be tested for their ability to induce exon 26 skipping.
  • TABLE 21
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H26A UGC UUU CUG UAA UUC AUC Needs testing
    (+132+156) UGG AGU U
    H26A CCU CCU UUC UGG CAU AGA Needs testing
    (−07+19) CCU UCC AC
    H26A UGU GUC AUC CAU UCG UGC Faint
    (+68+92) AUC UCU G skipping at
    600 nM
  • Antisense Oligonucleotides Directed at Exon 27
  • Antisense oligonucleotides directed at exon 27 were prepared using similar methods as described above. Table 22 below outlines the antisense oligonucleotides directed at exon 27 that are yet to be tested for their ability to induce exon 27 skipping.
  • TABLE 22
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H27A UUA AGG CCU CUU GUG CUA Needs testing
    (+82+106) CAG GUG G
    H27A GGG CCU CUU CUU UAG CUC Faint
    (−4+19) UCU GA skipping at
    600 and
    300 nM
    H27D GAC UUC CAA AGU CUU GCA v. strong
    (+19−03) UUU C skipping
    at 600
    and 300 nM
  • Antisense Oligonucleotides Directed at Exon 28
  • Antisense oligonucleotides directed at exon 28 were prepared using similar methods as described above. Table 23 below outlines the antisense oligonucleotides directed at exon 28 that are yet to be tested for their ability to induce exon 28 skipping.
  • TABLE 23
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H28A GCC AAC AUG CCC AAA CUU v. strong
    (−05+19) CCU AAG skipping at
    600 and
    300 nM
    H28A CAG AGA UUU CCU CAG CUC Needs testing
    (+99+124) CGC CAG GA
    H28D CUU ACA UCU AGC ACC UCA v. strong
    (+16−05) GAG skipping
    at 600
    and 300 nM
  • Antisense Oligonucleotides Directed at Exon 29
  • Antisense oligonucleotides directed at exon 29 were prepared using similar methods as described above. Table 24 below outlines the antisense oligonucleotides directed at exon 29 that are yet to be tested for their ability to induce exon 29 skipping.
  • TABLE 24
    Antisense
    oligo- Ability to
    nucleotide induce
    name Sequence skipping
    H29A UCC GCC AUC UGU UAG GGU Needs testing
    (+57+81) CUG UGC C
    H29A AUU UGG GUU AUC CUC UGA v. strong
    (+18+42) AUG UCG C skipping at
    600 and
    300 nM
    H29D CAU ACC UCU UCA UGU AGU v. strong
    (+17−05) UCC C skipping
    at 600
    and 300 nM
  • Antisense Oligonucleotides Directed at Exon 30
  • Antisense oligonucleotides directed at exon 30 were prepared using similar methods as described above. Table 25 below outlines the antisense oligonucleotides directed at exon 30 that are yet to be tested for their ability to induce exon 30 skipping.
  • TABLE 25
    Antisense
    oligonucleotide Ability to induce
    name Sequence skipping
    H30A(+122 +147) CAU UUG AGC UGC GUC CAC CUU Needs testing
    GUC UG
    H30A(+25 +50) UCC UGG GCA GAC UGG AUG CUC Very strong skipping at
    UGU UC 600 and 300 nM.
    H30D(+19 −04) UUG CCU GGG CUU CCU GAG GCA Very strong skipping at
    UU 600 and 300 nM.
  • Antisense Oligonucleotides Directed at Exon 31
  • Antisense oligonucleotides directed at exon 31 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 13 illustrates differing efficiencies of two antisense molecules directed at exon 31 acceptor splice site and a “cocktail” of exon 31 antisense oligonucleotides at varying concentrations. H31D(+03−22) [SEQ ID NO:124] substantially induced exon 31 skipping when delivered into cells at a concentration of 20 nM. Table 26 below also includes other antisense molecules tested at a concentration of 100 and 300 nM. These antisense molecules showed a variable ability to induce exon skipping.
  • TABLE 26
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H31D(+06 −18) UUC UGA AAU AAC AUA UAC CUG UGC Skipping to 
    300 nM
    H31D(+03 −22) UAG UUU CUG AAA UAA CAU AUA CCU G Skipping to 
     20 nM
    H31A(+05 +25) GAC UUG UCA AAU CAG AUU GGA No skipping
    H31D(+04 −20) GUU UCU GAA AUA ACA UAU ACC UGU Skipping to 
    300 nM
  • Antisense Oligonucleotides Directed at Exon 32
  • Antisense oligonucleotides directed at exon 32 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H32D(+04−16) [SEQ ID NO:127] and H32A(+49+73) [SEQ ID NO:130] induced exon 32 skipping when delivered into cells at a concentration of 300 nM. Table 27 below also shows other antisense molecules tested at a concentration of 100 and 300 nM. These antisense molecules did not show an ability to induce exon skipping.
  • TABLE 27
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H32D(+04 −16) CAC CAG AAA UAC AUA CCA CA Skipping to 
    300 nM
    H32A(+151 +170) CAA UGA UUU AGC UGU GAC UG No skipping
    H32A(+10 +32) CGA AAC UUC AUG GAG ACA UCU UG No skipping
    H32A(+49 +73) CUU GUA GAC GCU GCU CAA AAU Skipping to 
    UGG C 300 nM
  • Antisense Oligonucleotides Directed at Exon 33
  • Antisense oligonucleotides directed at exon 33 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 14 shows differing efficiencies of two antisense molecules directed at exon 33 acceptor splice site. H33A(+64+88) [SEQ ID NO:134] substantially induced exon 33 skipping when delivered into cells at a concentration of 10 nM. Table 28 below includes other antisense molecules tested at a concentration of 100, 200 and 300 nM. These antisense molecules showed a variable ability to induce exon skipping.
  • TABLE 28
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H33D(+09 −11) CAU GCA CAC ACC UUU GCU CC No skipping
    H33A(+53 +76) UCU GUA CAA UCU GAC GUC CAG UCU Skipping to 
    200 nM
    H33A(+30 +56) GUC UUU AUC ACC AUU UCC ACU UCA Skipping to 
    GAC 200 nM
    H33A(+64 +88) CCG UCU GCU UUU UCU GUA CAA UCU Skipping to 
    G  10 nM
  • Antisense Oligonucleotides Directed at Exon 34
  • Antisense oligonucleotides directed at exon 34 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • Table 29 below includes antisense molecules tested at a concentration of 100 and 300 nM. These antisense molecules showed a variable ability to induce exon skipping.
  • TABLE 29
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H34A(+83 +104) UCC AUA UCU GUA GCU GCC AGC C No skipping
    H34A(+143 +165) CCA GGC AAC UUC AGA AUC CAA AU No skipping
    H34A(−20 +10) UUU CUG UUA CCU GAA AAG AAU UAU AAU Not tested
    GAA
    H34A(+46 +70) CAU UCA UUU CCU UUC GCA UCU UAC G Skipping to
    300 nM
    H34A(+95 +120) UGA UCU CUU UGU CAA UUC CAU AUC UG Skipping to
    300 nM
    H34D(+10 −20) UUC AGU GAU AUA GGU UUU ACC UUU Not tested
    CCC CAG
    H34A(+72 +96) CUG UAG CUG CCA GCC AUU CUG UCA AG No skipping
  • Antisense Oligonucleotides Directed at Exon 35
  • Antisense oligonucleotides directed at exon 35 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 15 shows differing efficiencies of antisense molecules directed at exon 35 acceptor splice site. H35A(+24+43) [SEQ ID NO:144] substantially induced exon 35 skipping when delivered into cells at a concentration of 20 nM. Table 30 below also includes other antisense molecules tested at a concentration of 100 and 300 nM. These antisense molecules showed no ability to induce exon skipping.
  • TABLE 30
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H35A(+141 +161) UCU UCU GCU CGG GAG GUG ACA Skipping to
    20 nM
    H35A(+116 +135) CCA GUU ACU AUU CAG AAG AC No skipping
    H35A(+24 +43) UCU UCA GGU GCA CCU UCU GU No skipping
  • Antisense Oligonucleotides Directed at Exon 36
  • Antisense oligonucleotides directed at exon 36 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • Antisense molecule H36A(+26+50) [SEQ ID NO:145] induced exon 36 skipping when delivered into cells at a concentration of 300 nM, as shown in FIG. 16.
  • Antisense Oligonucleotides Directed at Exon 37
  • Antisense oligonucleotides directed at exon 37 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 17 shows differing efficiencies of two antisense molecules directed at exon 37 acceptor splice site. H37A(+82+105) [SEQ ID NO:148] and H37A(+134+157) [SEQ ID NO:149] substantially induced exon 37 skipping when delivered into cells at a concentration of 10 nM. Table 31 below shows the antisense molecules tested.
  • TABLE 31
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H37A(+26 +50) CGU GUA GAG UCC ACC UUU GGG CGU A No skipping
    H37A(+82 +105) UAC UAA UUU CCU GCA GUG GUC ACC Skipping to
    10 nM
    H37A(+134 +157) UUC UGU GUG AAA UGG CUG CAA AUC Skipping to
    10 nM
  • Antisense Oligonucleotides Directed at Exon 38
  • Antisense oligonucleotides directed at exon 38 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 18 illustrates antisense molecule H38A(+88+112) [SEQ ID NO:152], directed at exon 38 acceptor splice site. H38A(+88+112) substantially induced exon 38 skipping when delivered into cells at a concentration of 10 nM. Table 32 below shows the antisense molecules tested and their ability to induce exon skipping.
  • TABLE 32
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H38A(−01 +19) CCU UCA AAG GAA UGG AGG CC No skipping
    H38A(+59 +83) UGC UGA AUU UCA GCC UCC AGU GGU Skipping to
    U 10 nM
    H38A(+88 +112) UGA AGU CUU CCU CUU UCA GAU UCA C Skipping to
    10 nM
  • Antisense Oligonucleotides Directed at Exon 39
  • Antisense oligonucleotides directed at exon 39 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H39A(+62+85) [SEQ ID NO:153] induced exon 39 skipping when delivered into cells at a concentration of 100 nM. Table 33 below shows the antisense molecules tested and their ability to induce exon skipping.
  • TABLE 33
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H39A(+62 +85) CUG GCU UUC UCU CAU CUG UGA UUC Skipping to
    100 nM
    H39A(+39 +58) GUU GUA AGU UGU CUC CUC UU No skipping
    H39A(+102 +121) UUG UCU GUA ACA GCU GCU GU No skipping
    H39D(+10 −10) GCU CUA AUA CCU UGA GAG CA Skipping to
    300 nM
  • Antisense Oligonucleotides Directed at Exon 40
  • Antisense oligonucleotides directed at exon 40 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 19 illustrates antisense molecule H40A(−05+17) [SEQ ID NO:157] directed at exon 40 acceptor splice site. H40A(−05+17) and H40A(+129+153) [SEQ ID NO:158] both substantially induced exon 40 skipping when delivered into cells at a concentration of 5 nM.
  • Antisense Oligonucleotides Directed at Exon 42
  • Antisense oligonucleotides directed at exon 42 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 20 illustrates antisense molecule H42A(−04+23) [SEQ ID NO:159], directed at exon 42 acceptor splice site. H42A(−4+23) and H42D(+19−02) [SEQ ID NO:161] both induced exon 42 skipping when delivered into cells at a concentration of 5 nM. Table 34 below shows the antisense molecules tested and their ability to induce exon 42 skipping.
  • TABLE 34
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H42A(−4 +23) AUC GUU UCU UCA CGG ACA GUG UGC Skipping to
    UGG   5 nM
    H42A(+86 +109) GGG CUU GUG AGA CAU GAG UGA UUU Skipping to
    100 nM
    H42D(+19 −02) A CCU UCA GAG GAC UCC UCU UGC Skipping to
      5 nM
  • Antisense Oligonucleotides Directed at Exon 43
  • Antisense oligonucleotides directed at exon 43 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H43A(+101+120) [SEQ ID NO:163] induced exon 43 skipping when delivered into cells at a concentration of 25 nM. Table 35 below includes the antisense molecules tested and their ability to induce exon 43 skipping.
  • TABLE 35
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H43D(+10 −15) UAU GUG UUA CCU ACC CUU GUC GGU C Skipping to
    100 nM
    H43A(+101 +120) GGA GAG AGC UUC CUG UAG CU Skipping to
     25 nM
    H43A(+78 +100) UCA CCC UUU CCA CAG GCG UUG CA Skipping to
    200 nM
  • Antisense Oligonucleotides Directed at Exon 44
  • Antisense oligonucleotides directed at exon 44 were prepared using similar methods as described above. Testing for the ability of these antisense molecules to induce exon 44 skipping is still in progress. The antisense molecules under review are shown as SEQ ID Nos: 165 to 167 in Table 1A.
  • Antisense Oligonucleotides Directed at Exon 45
  • Antisense oligonucleotides directed at exon 45 were prepared using similar methods as described above. Testing for the ability of these antisense molecules to induce exon 45 skipping is still in progress. The antisense molecules under review are shown as SEQ ID Nos: 207 to 211 in Table 1A.
  • Antisense Oligonucleotides Directed at Exon 46
  • Antisense oligonucleotides directed at exon 46 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 21 illustrates the efficiency of one antisense molecule directed at exon 46 acceptor splice site. Antisense oligonucleotide H46A(+86+115) [SEQ ID NO:203] showed very strong ability to induce exon 46 skipping. Table 36 below includes antisense molecules tested. These antisense molecules showed varying ability to induce exon 46 skipping.
  • TABLE 36
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H46D(+16 −04) UUA CCU UGA CUU GCU CAA GC No skipping
    H46A(+90 +109) UCC AGG UUC AAG UGG GAU AC No skipping
    H46A(+86 +115) CUC UUU UCC AGG UUC AAG UGG GAU Good skipping
    ACU AGC to 100 nM
    H46A(+107 +137) CAA GCU UUU CUU UUA GUU GCU GCU Good skipping
    CUU UUC C to 100 nM
    H46A(−10 +20) UAU UCU UUU GUU CUU CUA GCC UGG Weak skipping
    AGA AAG
    H46A(+50 +77) CUG CUU CCU CCA ACC AUA AAA CAA Weak skipping
    AUU C
  • Antisense Oligonucleotides Directed at Exon 47
  • Antisense oligonucleotides directed at exon 47 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • H47A(+76+100) [SEQ ID NO:170] and H47A(−09+12) [SEQ ID NO:172] both induced exon 47 skipping when delivered into cells at a concentration of 200 nM. H47D(+25−02) [SEQ ID NO: 171] is yet to be prepared and tested.
  • Antisense Oligonucleotides Directed at Exon 50
  • Antisense oligonucleotides directed at exon 50 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • Antisense oligonucleotide molecule H50(+02+30) [SEQ ID NO: 173] was a strong inducer of exon skipping. Further, H50A(+07+33) [SEQ ID NO:174] and H50D(+07−18) [SEQ ID NO:175] both induced exon 50 skipping when delivered into cells at a concentration of 100 nM.
  • Antisense Oligonucleotides Directed at Exon 51
  • Antisense oligonucleotides directed at exon 51 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 22 illustrates differing efficiencies of two antisense molecules directed at exon 51 acceptor splice site. Antisense oligonucleotide H51A(+66+90) [SEQ ID NO:180] showed the stronger ability to induce exon 51 skipping. Table 37 below includes antisense molecules tested at a concentration range of 25, 50, 100, 300 and 600 nM. These antisense molecules showed varying ability to induce exon skipping. The strongest inducers of exon skipping were antisense oligonucleotide H51A(+61+90) [SEQ ID NO: 179] and H51A(+66+95) [SEQ ID NO: 179].
  • TABLE 37
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H51A(−01 +25) ACC AGA GUA ACA GUC UGA GUA GGA GC Faint
    skipping
    H51D(+16 −07) CUC AUA CCU UCU GCU UGA UGA UC Skipping at
    300 nM
    H51A(+111 +134) UUC UGU CCA AGC CCG GUU GAA AUC Needs re-
    testing
    H51A(+61 +90) ACA UCA AGG AAG AUG GCA UUU CUA GUU Very strong
    UGG skipping
    H51A(+66 +90) ACA UCA AGG AAG AUG GCA UUU CUA G skipping
    H51A(+66 +95) CUC CAA CAU CAA GGA AGA UGG CAU UUC Very strong
    UAG skipping
    H51D(+08 −17) AUC AUU UUU UCU CAU ACC UUC UGC U No skipping
    H51A/D(+08 −17) & AUC AUU UUU UCU CAU ACC UUC UGC UAG No skipping
    (−15 +?) GAG CUA AAA
    H51A(+175 +195) CAC CCA CCA UCA CCC UCY GUG No skipping
    H51A(+199 +220) AUC AUC UCG UUG AUA UCC UCA A No skipping
  • Antisense Oligonucleotides Directed at Exon 52
  • Antisense oligonucleotides directed at exon 52 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 22 also shows differing efficiencies of four antisense molecules directed at exon 52 acceptor splice site. The most effective antisense oligonucleotide for inducing exon 52 skipping was H52A(+17+37) [SEQ ID NO:188].
  • Table 38 below shows antisense molecules tested at a concentration range of 50, 100, 300 and 600 nM. These antisense molecules showed varying ability to induce exon 50 skipping. Antisense molecules H52A(+12+41) [SEQ ID NO:187] and H52A(+17+37) [SEQ ID NO:188] showed the strongest exon 50 skipping at a concentration of 50 nM.
  • TABLE 38
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H52A(−07 +14) UCC UGC AUU GUU GCC UGU AAG No skipping
    H52A(+12 +41) UCC AAC UGG GGA CGC CUC UGU UCC AAA Very strong
    UCC skipping
    H52A(+17 +37) ACU GGG GAC GCC UCU GUU CCA Skipping to
    50 nM
    H52A(+93 +112) CCG UAA UGA UUG UUC UAG CC No skipping
    H52D(+05 −15) UGU UAA AAA ACU UAC UUC GA No skipping
  • Antisense Oligonucleotides Directed at Exon 53
  • Antisense oligonucleotides directed at exon 53 were prepared and tested for their ability to induce exon skipping in human muscle cells using similar methods as described above.
  • FIG. 22 also shows antisense molecule H53A(+39+69) [SEQ ID NO:193] directed at exon 53 acceptor splice site. This antisense oligonucleotide was able to induce exon 53 skipping at 5, 100, 300 and 600 nM. A “cocktail” of three exon antisense oligonucleotides: —H53D(+23+47) [SEQ ID NO:195], H53A(+150+175) [SEQ ID NO:196] and H53A(+14−07) [SEQ ID NO:194], were also tested, as shown in FIG. 20 and exhibited an ability to induce exon skipping.
  • Table 39 below includes other antisense molecules tested at a concentration range of 50, 100, 300 and 600 nM. These antisense molecules showed varying ability to induce exon 53 skipping. Antisense molecule H53A(+39+69) [SEQ ID NO:193] induced the strongest exon 53 skipping.
  • TABLE 39
    Antisense Ability to
    oligonucleotide induce
    name Sequence skipping
    H53A(+45 +69) CAU UCA ACU GUU GCC UCC GGU UCU G Faint 
    skipping at
     50 nM
    H53A(+39 +62) CUG UUG CCU CCG GUU CUG AAG GUG Faint 
    skipping at
     50 nM
    H53A(+39 +69) CAU UCA ACU GUU GCC UCC GGU UCU Strong 
    GAA GGU G skipping to
     50 nM
    H53D(+14 −07) UAC UAA CCU UGG UUU CUG UGA Very faint
    skipping to
     50 nM
    H53A(+23 +47) CUG AAG GUG UUC UUG UAC UUC AUC C Very faint
    skipping to
     50 nM
    H53A(+150 +176) UGU AUA GGG ACC CUC CUU CCA UGA Very faint
    CUC skipping to
     50 nM
    H53D(+20 −05) CUA ACC UUG GUU UCU GUG AUU UUC U Not made yet
    H53D(+09 −18) GGU AUC UUU GAU ACU AAC CUU GGU Faint at
    UUC 600 nM
    H53A(−12 +10) AUU CUU UCA ACU AGA AUA AAA G No skipping
    H53A(−07 +18) GAU UCU GAA UUC UUU CAA CUA GAA U No skipping
    H53A(+07 +26) AUC CCA CUG AUU CUG AAU UC No skipping
    H53A(+124 +145) UUG GCU CUG GCC UGU CCU AAG A No skipping

Claims (34)

  1. 1-14. (canceled)
  2. 15. An isolated antisense oligonucleotide of 10 to 50 nucleotides in length comprising a sequence that is specifically hybridizable to an exon 45 target region of the Dystrophin gene designated as annealing site H45A(−6+20), H45A(+91+110), H45A(+125+151), H45D(+16−04), H45A(+71+90) or a combination thereof.
  3. 16. The antisense oligonucleotide of claim 15, comprising SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210 or SEQ ID NO:211 wherein the uracil bases are optionally thymine bases.
  4. 17. The antisense oligonucleotide of claim 16, wherein the uracil bases are thymine bases.
  5. 18. The antisense oligonucleotide of claim 15, which is 20 to 31 nucleotides in length.
  6. 19. The antisense oligonucleotide of claim 15, which is 25 to 31 nucleotides in length.
  7. 20. The antisense oligonucleotide of claim 15, wherein the oligonucleotide does not activate RNase H.
  8. 21. The antisense oligonucleotide of claim 15, comprising a non-natural backbone.
  9. 22. The antisense oligonucleotide of claim 21, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties.
  10. 23. The antisense oligonucleotide of claim 22, wherein the non-natural moieties are morpholinos.
  11. 24. The antisense oligonucleotide of claim 15, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.
  12. 25. The antisense oligonucleotide of claim 24, wherein the non-natural inter-nucleotide linkages are modified phosphates.
  13. 26. The antisense oligonucleotide of claim 25, wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.
  14. 27. The antisense oligonucleotide of claim 26, wherein the modified phosphates are phosphoramidates.
  15. 28. The antisense oligonucleotide of claim 26, wherein the modified phosphates are phosphoromorpholidates.
  16. 29. The antisense oligonucleotide of claim 15, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties and the internucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.
  17. 30. The antisense oligonucleotide of claim 29, wherein the non-natural moieties are morpholinos and the non-natural internucleotide linkages are modified phosphates.
  18. 31. The antisense oligonucleotide of claim 30, wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.
  19. 32. The antisense oligonucleotide of claim 31, wherein the modified phosphates are phosphoramidates.
  20. 33. The antisense oligonucleotide of claim 31, wherein the modified phosphates are phosphoromorpholidates.
  21. 34. The antisense oligonucleotide of claim 15, wherein the oligonucleotide is a 2′-O-methyl-oligoribonucleotide.
  22. 35. The antisense oligonucleotide claim 15, wherein the oligonucleotide is a peptide nucleic acid.
  23. 36. The antisense oligonucleotide of claim 15, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.
  24. 37. The antisense oligonucleotide of claim 36, wherein the oligonucleotide is chemically linked to a polyethylene glycol molecule.
  25. 38. The antisense oligonucleotide of claim 15, wherein the antisense oligonucleotide consists of the sequence identified as SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210 or SEQ ID NO:211, wherein the uracil bases are optionally thymine bases.
  26. 39. The antisense oligonucleotide of claim 38, wherein the uracil bases are thymine bases.
  27. 40. A pharmaceutical composition, comprising the antisense oligonucleotide of claim 15 and a pharmaceutically acceptable carrier.
  28. 41. The pharmaceutical composition of claim 40, wherein the pharmaceutically acceptable carrier is phosphate-buffered saline.
  29. 42. A method of inducing exon-skipping of dystrophin exon 45 comprising delivering an antisense oligonucleotide of claim 15 to a cell, thereby inducing exon-skipping of the dystrophin exon.
  30. 43. The method of claim 42, wherein the cell is a human muscle cell.
  31. 44. The method of claim 43, wherein the human muscle cell is in a patient.
  32. 45. The method of claim 44, wherein the patient has muscular dystrophy.
  33. 46. The method of claim 45, wherein the muscular dystrophy is Duchenne Muscular Dystrophy.
  34. 47. A pharmaceutically acceptable salt of the antisense oligonucleotide of claim 15.
US13168857 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof Abandoned US20110263686A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004903474 2004-06-28
AU2004903474 2004-06-28
PCT/AU2005/000943 WO2006000057A1 (en) 2004-06-28 2005-06-28 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US57069108 true 2008-01-15 2008-01-15
US12837359 US8232384B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13168857 US20110263686A1 (en) 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US13168857 US20110263686A1 (en) 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13741150 US20130253033A1 (en) 2004-06-28 2013-01-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826613 US20130217755A1 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826880 US9175286B2 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13902376 US20130253180A1 (en) 2004-06-28 2013-05-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14086859 US20140080898A1 (en) 2004-06-28 2013-11-21 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14178059 US20140155587A1 (en) 2004-06-28 2014-02-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273379 US20140243516A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273318 US20140243515A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316609 US9024007B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316603 US9018368B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14317952 US9035040B2 (en) 2004-06-28 2014-06-27 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14740097 US9605262B2 (en) 2004-06-28 2015-06-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852090 US9441229B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852149 US9249416B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857561 US9447415B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857555 US9422555B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14858250 US20160002635A1 (en) 2004-06-28 2015-09-18 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274772 US20170009234A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274719 US20170009233A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15467443 US20180051282A1 (en) 2004-06-28 2017-03-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15705172 US9994851B2 (en) 2004-06-28 2017-09-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US12837359 Continuation 2008-01-15
US12837359 Continuation US8232384B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13741150 Continuation US20130253033A1 (en) 2004-06-28 2013-01-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826613 Continuation US20130217755A1 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Publications (1)

Publication Number Publication Date
US20110263686A1 true true US20110263686A1 (en) 2011-10-27

Family

ID=35781530

Family Applications (37)

Application Number Title Priority Date Filing Date
US11570691 Active 2026-02-23 US7807816B2 (en) 2004-06-28 2005-06-28 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12837356 Active 2026-04-02 US8524880B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12837359 Active US8232384B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12860078 Active US7960541B2 (en) 2004-06-28 2010-08-20 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13168857 Abandoned US20110263686A1 (en) 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13168863 Active US8455634B2 (en) 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270744 Active US8476423B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270500 Active US8450474B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270531 Abandoned US20120029058A1 (en) 2004-06-28 2011-10-11 Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof
US13270992 Active US8486907B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13271080 Active US8455636B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270937 Active US8455635B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13727415 Abandoned US20130116310A1 (en) 2004-06-28 2012-12-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13741150 Abandoned US20130253033A1 (en) 2004-06-28 2013-01-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826613 Abandoned US20130217755A1 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826880 Active US9175286B2 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13902376 Abandoned US20130253180A1 (en) 2004-06-28 2013-05-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13963578 Abandoned US20130331438A1 (en) 2004-06-28 2013-08-09 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14086859 Abandoned US20140080898A1 (en) 2004-06-28 2013-11-21 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14178059 Abandoned US20140155587A1 (en) 2004-06-28 2014-02-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14223634 Abandoned US20150057330A1 (en) 2004-06-28 2014-03-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273318 Abandoned US20140243515A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273379 Abandoned US20140243516A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316603 Active US9018368B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316609 Active US9024007B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14317952 Active US9035040B2 (en) 2004-06-28 2014-06-27 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14740097 Active US9605262B2 (en) 2004-06-28 2015-06-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852090 Active US9441229B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852149 Active US9249416B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857555 Active US9422555B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857561 Active US9447415B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14858250 Abandoned US20160002635A1 (en) 2004-06-28 2015-09-18 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274719 Abandoned US20170009233A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274772 Pending US20170009234A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15467443 Abandoned US20180051282A1 (en) 2004-06-28 2017-03-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15673019 Pending US20180163205A1 (en) 2004-06-28 2017-08-09 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15705172 Active US9994851B2 (en) 2004-06-28 2017-09-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US11570691 Active 2026-02-23 US7807816B2 (en) 2004-06-28 2005-06-28 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12837356 Active 2026-04-02 US8524880B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12837359 Active US8232384B2 (en) 2004-06-28 2010-07-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US12860078 Active US7960541B2 (en) 2004-06-28 2010-08-20 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Family Applications After (32)

Application Number Title Priority Date Filing Date
US13168863 Active US8455634B2 (en) 2004-06-28 2011-06-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270744 Active US8476423B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270500 Active US8450474B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270531 Abandoned US20120029058A1 (en) 2004-06-28 2011-10-11 Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof
US13270992 Active US8486907B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13271080 Active US8455636B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13270937 Active US8455635B2 (en) 2004-06-28 2011-10-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13727415 Abandoned US20130116310A1 (en) 2004-06-28 2012-12-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13741150 Abandoned US20130253033A1 (en) 2004-06-28 2013-01-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826613 Abandoned US20130217755A1 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13826880 Active US9175286B2 (en) 2004-06-28 2013-03-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13902376 Abandoned US20130253180A1 (en) 2004-06-28 2013-05-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US13963578 Abandoned US20130331438A1 (en) 2004-06-28 2013-08-09 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14086859 Abandoned US20140080898A1 (en) 2004-06-28 2013-11-21 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14178059 Abandoned US20140155587A1 (en) 2004-06-28 2014-02-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14223634 Abandoned US20150057330A1 (en) 2004-06-28 2014-03-24 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273318 Abandoned US20140243515A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14273379 Abandoned US20140243516A1 (en) 2004-06-28 2014-05-08 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316603 Active US9018368B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14316609 Active US9024007B2 (en) 2004-06-28 2014-06-26 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14317952 Active US9035040B2 (en) 2004-06-28 2014-06-27 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14740097 Active US9605262B2 (en) 2004-06-28 2015-06-15 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852090 Active US9441229B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14852149 Active US9249416B2 (en) 2004-06-28 2015-09-11 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857555 Active US9422555B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14857561 Active US9447415B2 (en) 2004-06-28 2015-09-17 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US14858250 Abandoned US20160002635A1 (en) 2004-06-28 2015-09-18 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274719 Abandoned US20170009233A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15274772 Pending US20170009234A1 (en) 2004-06-28 2016-09-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15467443 Abandoned US20180051282A1 (en) 2004-06-28 2017-03-23 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15673019 Pending US20180163205A1 (en) 2004-06-28 2017-08-09 Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US15705172 Active US9994851B2 (en) 2004-06-28 2017-09-14 Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Country Status (6)

Country Link
US (37) US7807816B2 (en)
EP (6) EP1766010B1 (en)
DE (1) DE602005026386D1 (en)
DK (2) DK2206781T3 (en)
ES (3) ES2564185T3 (en)
WO (1) WO2006000057A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147952A1 (en) * 2003-03-21 2006-07-06 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US20090228998A1 (en) * 2000-09-21 2009-09-10 Academisch Ziekenhuis Leiden Induction of exon skipping in eukaryotic cells
US20100130591A1 (en) * 2008-10-24 2010-05-27 Peter Sazani Multiple exon skipping compositions for dmd
US8637483B2 (en) 2009-11-12 2014-01-28 The University Of Western Australia Antisense molecules and methods for treating pathologies
US8802645B2 (en) 2009-12-24 2014-08-12 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
US9018368B2 (en) 2004-06-28 2015-04-28 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9139828B2 (en) 2008-05-14 2015-09-22 Prosensa Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US9217148B2 (en) 2013-03-14 2015-12-22 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US9243245B2 (en) 2007-10-26 2016-01-26 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
US9506058B2 (en) 2013-03-15 2016-11-29 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282699B1 (en) * 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
DK2351844T3 (en) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Compositions for enhancing the transport and antisense efficiency of nucleic acid into cells
US20050234002A1 (en) 2004-01-23 2005-10-20 Mourich Dan V Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2006086667A3 (en) 2005-02-09 2007-02-22 Avi Bio Pharma Inc Antisense composition and method for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
CA2660523A1 (en) 2006-08-11 2008-02-14 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US20100190689A1 (en) * 2006-09-21 2010-07-29 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN103212085A (en) 2007-07-12 2013-07-24 普罗森那技术公司 Molecules for targeting compounds to various selected organs or tissues
JP2010533170A (en) * 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. Organs The compound selected various, molecules to target tissue or tumor cells
DK2344637T4 (en) * 2008-10-27 2018-04-23 Biomarin Tech Bv Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA
US7989608B2 (en) 2007-12-28 2011-08-02 Avi Biopharma Inc. Immunomodulatory agents and methods of use
CN101980726A (en) 2008-02-08 2011-02-23 普罗森那控股公司 Methods and means for treating DNA repeat instability associated genetic disorders
WO2009101399A1 (en) * 2008-02-12 2009-08-20 Isis Innovation Limited Treatment of muscular dystrophy using peptide nucleic acid ( pna)
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN102625840A (en) * 2009-04-10 2012-08-01 伯尔尼大学 Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease
JP2012524540A (en) * 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. Oligonucleotides containing inosine for the treatment of Dmd
WO2010150231A1 (en) * 2009-06-26 2010-12-29 Universita' Degli Studi Di Ferrara Antisense oligonucleotides capable of inducing exon skipping and the use thereof as a medicament for the treatment of duchenne muscular dystrophy (dmd)
CN103619356B (en) 2011-05-05 2017-09-12 萨勒普塔医疗公司 Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US20120172415A1 (en) * 2009-08-31 2012-07-05 Thomas Voit Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
US8586560B2 (en) * 2009-10-16 2013-11-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Exon skipping therapy for dysferlinopathies
US20120270930A1 (en) 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
CN105125572A (en) 2009-12-18 2015-12-09 箭头研究公司 Organic compositions to treat hsf1-related diseases
WO2011078797A3 (en) * 2009-12-22 2011-11-10 Singapore Health Services Pte. Ltd Antisense oligonucleotides and uses threreof
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2011154851A1 (en) * 2010-06-08 2011-12-15 Amsterdam Molecular Therapeutics (Amt) Ip B.V. MODIFIED snRNAs FOR USE IN THERAPY
WO2012018257A1 (en) * 2010-08-05 2012-02-09 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
JP5363655B2 (en) 2010-09-01 2013-12-11 日本新薬株式会社 Antisense nucleic acid
DK2426203T3 (en) 2010-09-02 2016-11-07 Université de Mons Agents that are useful in the treatment of muscular dystrophy, facioscapulohumeral
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
WO2012065143A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EP2672977A1 (en) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
EP2750715A4 (en) 2011-08-30 2015-08-05 Univ California Identification of small molecules that enhance therapeutic exon skipping
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201117880D0 (en) * 2011-10-17 2011-11-30 Ucl Business Plc Antisense oligonucleotides
KR20140097398A (en) 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 Functionally-modified oligonucleotides and subunits thereof
CN104024414A (en) * 2011-12-28 2014-09-03 日本新药株式会社 Antisense nucleic acid
CN104203289A (en) * 2012-01-27 2014-12-10 普罗森萨科技有限公司 RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
DE102012103041A1 (en) 2012-04-10 2013-10-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum New isolated antisense-oligonucleotide comprising sequence that is hybridized to messenger RNA-splicing-sequence of mutation-bearing exons of pre-messenger RNA of titin-gene and induces skipping of exons, used to treat heart disease
EP2850186A4 (en) 2012-05-16 2016-01-27 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
EP2870246A2 (en) * 2012-07-03 2015-05-13 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
WO2014039189A1 (en) 2012-08-01 2014-03-13 Mcnally Elizabeth Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
KR20150099804A (en) 2012-12-20 2015-09-01 사렙타 쎄러퓨틱스 인코퍼레이티드 Improved exon skipping compositions for treating muscular dystrophy
WO2014153240A3 (en) 2013-03-14 2014-12-31 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
KR20160023765A (en) * 2013-06-05 2016-03-03 듀크 유니버시티 Rna-guided gene editing and gene regulation
WO2015171918A3 (en) * 2014-05-07 2016-01-07 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US20170306399A1 (en) 2014-06-10 2017-10-26 Erasmus University Medical Center Rotterdam Methods for characterizing alternatively or aberrantly spliced mrna isoforms
JP6208349B2 (en) 2014-06-17 2017-10-04 日本新薬株式会社 Antisense nucleic acid
JP2017527565A (en) 2014-09-07 2017-09-21 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. Methods and compositions for that attenuates gene expression regulatory antiviral transfer vector immune response
WO2016164602A1 (en) * 2015-04-08 2016-10-13 The University Of Chicago Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping
WO2017205513A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
WO2017213854A1 (en) 2016-05-24 2017-12-14 Sarepta Therapeutics, Inc. Pharmaceutical composition comprising eteplirsen
WO2017205496A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing oligomers
WO2018005805A1 (en) 2016-06-30 2018-01-04 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
DE3650699D1 (en) 1985-03-15 1998-10-22 Antivirals Inc Immunotestmittel for polynucleotide and methods
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
JP2652732B2 (en) 1991-09-30 1997-09-10 アロン化成株式会社 Blow molding method
US5869252A (en) 1992-03-31 1999-02-09 Abbott Laboratories Method of multiplex ligase chain reaction
EP1018649A3 (en) * 1992-03-31 2000-11-29 Abbott Laboratories Immunochromatographic device and method for multiplex detection of multiple analytes
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
EP0786522A3 (en) 1992-07-17 1997-08-27 Ribozyme Pharm Inc
DE69435005T2 (en) 1993-05-11 2008-04-17 The University Of North Carolina At Chapel Hill Antisense oligonucleotides prevent aberrant splicing and their use
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
GB9510718D0 (en) 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
CN1214688A (en) 1996-02-14 1999-04-21 伊希斯药物有限公司 Sugar-modified gapped oligonucleotides
WO1997034638A1 (en) 1996-03-20 1997-09-25 The Regents Of The University Of California Antisense approach to gene inhibition
US6153436A (en) 1997-01-10 2000-11-28 The Board Of Trustees Of The University Of Arkansas Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
GB9819999D0 (en) 1998-09-14 1998-11-04 Univ London Treatment of cancer
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US20020049173A1 (en) 1999-03-26 2002-04-25 Bennett C. Frank Alteration of cellular behavior by antisense modulation of mRNA processing
JP2002529499A (en) 1998-11-13 2002-09-10 イーライ・リリー・アンド・カンパニー Method for the treatment of pain
CA2360997A1 (en) 1999-01-29 2000-08-03 Avi Biopharma, Inc. Non-invasive method for detecting target rna
JP2000325085A (en) 1999-05-21 2000-11-28 Jcr Pharmaceuticals Co Ltd Pharmaceutical composition for treatment of duchenne muscular dystrophy
JP2003502383A (en) 1999-06-21 2003-01-21 マードック チルドレンズ リサーチ インスティチュート The method for the prevention and / or treatment of medical disorders
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
CA2394758A1 (en) 1999-12-29 2001-07-05 A. James Mixson Histidine-containing copolymers enhance pharmaceutical agent delivery
US7049431B2 (en) 2000-01-04 2006-05-23 Avi Biopharma, Inc. Antisense antibacterial cell division composition and method
EP1263765A4 (en) 2000-03-28 2005-06-29 ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
JP4590033B2 (en) 2000-04-26 2010-12-01 日本ケミカルリサーチ株式会社 Duchenne muscular dystrophy treatment agent
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
DE60139394D1 (en) 2000-04-28 2009-09-10 Asklepios Biopharmaceutical In For the dystrophin minigene coding DNA sequences and methods for their use
EP1278761B1 (en) 2000-05-01 2005-04-06 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
EP1282699B1 (en) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
CA2651881A1 (en) 2006-05-10 2008-03-27 Avi Biopharma, Inc. Oligonucleotide analogs having cationic intersubunit linkages
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
JP4836366B2 (en) 2000-08-25 2011-12-14 日本ケミカルリサーチ株式会社 Duchenne muscular dystrophy treatment agent
US7264925B2 (en) 2000-08-30 2007-09-04 Avi Biopharma, Inc. Method for analysis of oligonucleotide analogs
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002024717A1 (en) 2000-09-20 2002-03-28 Isis Pharmaceuticals, Inc. Antisense modulation of flip-c expression
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US6689615B1 (en) 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
JP3781687B2 (en) 2001-02-23 2006-05-31 瑞夫 前田 How genetic diagnosis apparatus and genetic diagnosis
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US20030114401A1 (en) * 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of Ship-1 expression
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7314750B2 (en) 2002-11-20 2008-01-01 Affymetrix, Inc. Addressable oligonucleotide array of the rat genome
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
EP2392660A3 (en) 2002-11-25 2012-03-28 Masafumi Matsuo ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
WO2004049686A1 (en) 2002-11-25 2004-06-10 Telesector Resources Group, Inc. Methods and systems for notification of call to device
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
DK2351844T3 (en) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Compositions for enhancing the transport and antisense efficiency of nucleic acid into cells
ES2302898T3 (en) 2003-07-11 2008-08-01 Lbr Medbiotech B.V. Gene transfer to muscle cells mediated by receptor mannose 6-phosphate.
US7807801B2 (en) 2003-08-05 2010-10-05 Avi Biopharma Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050048495A1 (en) 2003-08-29 2005-03-03 Baker Brenda F. Isoform-specific targeting of splice variants
CA2538729A1 (en) 2003-09-12 2005-03-31 Avi Biopharma, Inc. Compound and method for treating androgen-independent prostate cancer
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
EP1766010B1 (en) 2004-06-28 2011-02-16 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
FR2873294B1 (en) 2004-07-26 2008-05-09 Greenpharma Sa Sa Association of drugs
FR2874384B1 (en) 2004-08-17 2010-07-30 Genethon adeno-associated viral vector to achieve the exon skipping in a gene encoding a protein is dispensable areas
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
WO2006086667A3 (en) 2005-02-09 2007-02-22 Avi Bio Pharma Inc Antisense composition and method for treating muscle atrophy
JP2008538500A (en) 2005-04-22 2008-10-30 アカデミス ツィーケンホイス ライデン By interference with interfering with RNA secondary structure for binding of SR proteins, modulation of exon recognition in pre-mRNA
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8501703B2 (en) 2005-08-30 2013-08-06 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
US8524676B2 (en) 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
EP1951872A2 (en) 2005-11-10 2008-08-06 The University of North Carolina at Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
WO2007133812A3 (en) 2005-12-30 2008-10-23 Gordon John Lutz Improved carriers for delivery of nucleic acid agents to cells and tissues
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20070265215A1 (en) 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2170363B1 (en) 2007-06-29 2018-08-08 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
DK2344637T4 (en) 2008-10-27 2018-04-23 Biomarin Tech Bv Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-MRNA
ES2639852T3 (en) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Means and methods to counter muscle disorders
WO2009101399A1 (en) 2008-02-12 2009-08-20 Isis Innovation Limited Treatment of muscular dystrophy using peptide nucleic acid ( pna)
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CA2740328A1 (en) 2008-10-24 2010-04-29 Avi Biopharma, Inc. Multiple exon skipping compositions for dmd
CA2746508A1 (en) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
CN102625840A (en) 2009-04-10 2012-08-01 伯尔尼大学 Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease
JP2012524540A (en) 2009-04-24 2012-10-18 プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. Oligonucleotides containing inosine for the treatment of Dmd
US9034838B2 (en) 2009-05-25 2015-05-19 Universita Degli Studi Di Roma “La Sapienza” miR-31 in duchenne muscular dystrophy therapy
EP2258863A1 (en) 2009-05-25 2010-12-08 Universita'Degli Studi di Roma "La Sapienza" miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
CN103619356B (en) 2011-05-05 2017-09-12 萨勒普塔医疗公司 Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2010150231A1 (en) 2009-06-26 2010-12-29 Universita' Degli Studi Di Ferrara Antisense oligonucleotides capable of inducing exon skipping and the use thereof as a medicament for the treatment of duchenne muscular dystrophy (dmd)
US20120172415A1 (en) 2009-08-31 2012-07-05 Thomas Voit Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
EP2488165B1 (en) 2009-10-14 2014-07-23 Universita' degli Studi di Ferrara Nanoparticle of the core-shell type suitable for delivering therapeutic oligonucleotides to target tissues and the use thereof for the preparation of a medicament for treating duchenne muscular dystrophy
CN103003430A (en) 2009-11-12 2013-03-27 西澳大利亚大学 Antisense molecules and methods for treating pathologies
CN102712928B (en) 2009-11-13 2017-08-04 萨雷普塔治疗公司 The antisense antiviral compounds and methods for treating influenza virus infections
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
JP5950818B2 (en) 2010-06-28 2016-07-13 正敏 萩原 Preventing and improving agents of genetic diseases
JP5363655B2 (en) 2010-09-01 2013-12-11 日本新薬株式会社 Antisense nucleic acid
JP5831455B2 (en) 2010-09-30 2015-12-09 日本新薬株式会社 Morpholino nucleic acid derivatives
EP2672977A1 (en) 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
EP2750715A4 (en) 2011-08-30 2015-08-05 Univ California Identification of small molecules that enhance therapeutic exon skipping
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
ES2535654T3 (en) 2011-10-13 2015-05-13 Association Institut De Myologie DNA phosphorothioate tricyclo
CN104024414A (en) 2011-12-28 2014-09-03 日本新药株式会社 Antisense nucleic acid
CN104203289A (en) 2012-01-27 2014-12-10 普罗森萨科技有限公司 RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US9920085B2 (en) 2012-03-20 2018-03-20 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
EP2870246A2 (en) 2012-07-03 2015-05-13 Prosensa Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
KR20150099804A (en) 2012-12-20 2015-09-01 사렙타 쎄러퓨틱스 인코퍼레이티드 Improved exon skipping compositions for treating muscular dystrophy
WO2014153240A3 (en) 2013-03-14 2014-12-31 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
CN105378081A (en) 2013-03-14 2016-03-02 萨勒普塔医疗公司 Exon skipping compositions for treating muscular dystrophy
WO2014144978A8 (en) 2013-03-15 2014-12-24 Sarepta Therapeutics, Inc. Improved compositions for treating muscular dystrophy
EP2986632B1 (en) 2013-04-20 2018-09-05 Research Institute at Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
EP3355892A1 (en) 2015-09-30 2018-08-08 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090228998A1 (en) * 2000-09-21 2009-09-10 Academisch Ziekenhuis Leiden Induction of exon skipping in eukaryotic cells
US8759507B2 (en) 2003-03-21 2014-06-24 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering RNA structure
US20060147952A1 (en) * 2003-03-21 2006-07-06 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
US9175286B2 (en) 2004-06-28 2015-11-03 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9605262B2 (en) 2004-06-28 2017-03-28 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9447415B2 (en) 2004-06-28 2016-09-20 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9422555B2 (en) 2004-06-28 2016-08-23 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9249416B2 (en) 2004-06-28 2016-02-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9018368B2 (en) 2004-06-28 2015-04-28 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9024007B2 (en) 2004-06-28 2015-05-05 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9035040B2 (en) 2004-06-28 2015-05-19 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9441229B2 (en) 2004-06-28 2016-09-13 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9994851B2 (en) 2004-06-28 2018-06-12 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9499818B2 (en) 2007-10-26 2016-11-22 BioMarin Technologies, B.V. Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene
US9926557B2 (en) 2007-10-26 2018-03-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
US9528109B2 (en) 2007-10-26 2016-12-27 Biomarin Technologies B.V. Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA
US9243245B2 (en) 2007-10-26 2016-01-26 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
US9139828B2 (en) 2008-05-14 2015-09-22 Prosensa Technologies B.V. Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US9234198B1 (en) 2008-10-24 2016-01-12 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US8865883B2 (en) 2008-10-24 2014-10-21 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US9434948B2 (en) 2008-10-24 2016-09-06 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US20100130591A1 (en) * 2008-10-24 2010-05-27 Peter Sazani Multiple exon skipping compositions for dmd
US9447417B2 (en) 2008-10-24 2016-09-20 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US8871918B2 (en) 2008-10-24 2014-10-28 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US9453225B2 (en) 2008-10-24 2016-09-27 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US9447416B2 (en) 2008-10-24 2016-09-20 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
US8637483B2 (en) 2009-11-12 2014-01-28 The University Of Western Australia Antisense molecules and methods for treating pathologies
US9758783B2 (en) 2009-11-12 2017-09-12 The University Of Western Australia Antisense molecules and methods for treating pathologies
US9228187B2 (en) 2009-11-12 2016-01-05 The University Of Western Australia Antisense molecules and methods for treating pathologies
US8802645B2 (en) 2009-12-24 2014-08-12 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
US9982257B2 (en) 2012-07-13 2018-05-29 Wave Life Sciences Ltd. Chiral control
US9217148B2 (en) 2013-03-14 2015-12-22 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US9506058B2 (en) 2013-03-15 2016-11-29 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy

Also Published As

Publication number Publication date Type
EP2206781A9 (en) 2013-02-06 application
EP2206781B1 (en) 2015-12-02 grant
US20110015253A1 (en) 2011-01-20 application
US7807816B2 (en) 2010-10-05 grant
US7960541B2 (en) 2011-06-14 grant
US20150353931A1 (en) 2015-12-10 application
US20110015258A1 (en) 2011-01-20 application
US20120022144A1 (en) 2012-01-26 application
EP3029142A1 (en) 2016-06-08 application
WO2006000057A1 (en) 2006-01-05 application
US20130274313A1 (en) 2013-10-17 application
EP3228711A1 (en) 2017-10-11 application
EP2500430A2 (en) 2012-09-19 application
US20140155587A1 (en) 2014-06-05 application
US9605262B2 (en) 2017-03-28 grant
US8455636B2 (en) 2013-06-04 grant
EP2206781A2 (en) 2010-07-14 application
US20130116310A1 (en) 2013-05-09 application
ES2564185T3 (en) 2016-03-18 grant
EP2500430A3 (en) 2013-02-13 application
US8232384B2 (en) 2012-07-31 grant
US20130253033A1 (en) 2013-09-26 application
US20150376616A1 (en) 2015-12-31 application
EP2206781A3 (en) 2013-01-23 application
US20140309284A1 (en) 2014-10-16 application
US20140243515A1 (en) 2014-08-28 application
US20180051282A1 (en) 2018-02-22 application
US8486907B2 (en) 2013-07-16 grant
US9994851B2 (en) 2018-06-12 grant
DK1766010T3 (en) 2011-06-06 grant
US20180002697A1 (en) 2018-01-04 application
US20160002631A1 (en) 2016-01-07 application
US20120029060A1 (en) 2012-02-02 application
US20150057330A1 (en) 2015-02-26 application
US20120022145A1 (en) 2012-01-26 application
US9018368B2 (en) 2015-04-28 grant
US20140243516A1 (en) 2014-08-28 application
EP2933332A1 (en) 2015-10-21 application
US20130217755A1 (en) 2013-08-22 application
US20170009234A1 (en) 2017-01-12 application
EP1766010A4 (en) 2010-01-20 application
DE602005026386D1 (en) 2011-03-31 grant
US20140309285A1 (en) 2014-10-16 application
DK2206781T3 (en) 2016-03-07 grant
US20120029057A1 (en) 2012-02-02 application
US9447415B2 (en) 2016-09-20 grant
US20120029058A1 (en) 2012-02-02 application
US8450474B2 (en) 2013-05-28 grant
US20140309283A1 (en) 2014-10-16 application
US9035040B2 (en) 2015-05-19 grant
US9422555B2 (en) 2016-08-23 grant
ES2627917T3 (en) 2017-08-01 grant
US20150376615A1 (en) 2015-12-31 application
EP2500430B1 (en) 2017-03-08 grant
EP1766010A1 (en) 2007-03-28 application
US20080200409A1 (en) 2008-08-21 application
ES2361325T3 (en) 2011-06-16 grant
US8524880B2 (en) 2013-09-03 grant
EP1766010B1 (en) 2011-02-16 grant
US20180163205A1 (en) 2018-06-14 application
US20130331438A1 (en) 2013-12-12 application
US9175286B2 (en) 2015-11-03 grant
US20120029059A1 (en) 2012-02-02 application
US20160002632A1 (en) 2016-01-07 application
US9441229B2 (en) 2016-09-13 grant
US8455635B2 (en) 2013-06-04 grant
US20160002635A1 (en) 2016-01-07 application
US8476423B2 (en) 2013-07-02 grant
US20110046203A1 (en) 2011-02-24 application
US20130253180A1 (en) 2013-09-26 application
US8455634B2 (en) 2013-06-04 grant
US20140080898A1 (en) 2014-03-20 application
US9249416B2 (en) 2016-02-02 grant
US20170009233A1 (en) 2017-01-12 application
US9024007B2 (en) 2015-05-05 grant
US20120041050A1 (en) 2012-02-16 application

Similar Documents

Publication Publication Date Title
Esau Inhibition of microRNA with antisense oligonucleotides
US5976879A (en) Antisense oligonucleotides which combat aberrant splicing and methods of using the same
US20040224405A1 (en) siRNA induced systemic gene silencing in mammalian systems
Muntoni et al. Targeting RNA to treat neuromuscular disease
US20090269755A1 (en) Means and method for inducing exon-skipping
US20110263682A1 (en) Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53
Pramono et al. Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence
US20100168206A1 (en) GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression
US8324371B2 (en) Oligomers
Popplewell et al. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene
WO2010050802A2 (en) Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50- 53.
WO2006113246A2 (en) Small activating rna molecules and methods of use
McClorey et al. Induced dystrophin exon skipping in human muscle explants
Harding et al. The influence of antisense oligonucleotide length on dystrophin exon skipping
Wilton et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript
Eckstein The versatility of oligonucleotides as potential therapeutics
Järver et al. A chemical view of oligonucleotides for exon skipping and related drug applications
Villemaire et al. Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides
US20120059042A1 (en) Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
US7879992B2 (en) Modification of MyD88 splicing using modified oligonucleotides
WO2006019430A2 (en) Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20090170793A1 (en) Artificial riboswitch for controlling pre-mrna splicing
WO2007095387A2 (en) Compositions and methods for inhibiting gene silencing by rna interference
EP2435583B1 (en) miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY
Popplewell et al. Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials